Liver Transplantation

Synbiotics After Liver Transplant Show No Clinical Benefit: Liver Transplant | July 2026

Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening intestinal barrier function. Earlier studies suggested potential benefits, but their findings have not been consistently replicated in clinical practice. Why was this study needed?: . Previous studies suggested synbiotics may reduce post-transplant bacterial infections, but the evidence was inconsistent. . Synbiotic therapy has not been widely adopted in liver transplant programs. . High-quality randomized controlled data were needed to validate their effectiveness. . It remained uncertain whether postoperative synbiotics improve clinically meaningful outcomes after liver transplantation. Results: In this randomized, double-blind, placebo-controlled trial, postoperative synbiotic supplementation for 14 days did not reduce bacterial infections compared with placebo. There were no significant differences between the groups in antibiotic use, acute rejection, hospital length of stay, or short-term survival. Per-protocol analyses yielded similar findings, confirming the absence of a meaningful clinical benefit. Synbiotic therapy was well tolerated but failed to improve postoperative outcomes. Clinical Impact: This study challenges earlier reports supporting routine synbiotic supplementation after liver transplantation. The findings indicate that postoperative synbiotics should not be recommended as standard care solely to prevent bacterial infections. Future research should focus on identifying specific patient populations, alternative microbiome-based interventions, or different treatment strategies that may offer greater clinical benefit. Bottom Line: Routine postoperative synbiotic supplementation does not reduce bacterial infections or improve short-term clinical outcomes after liver transplantation and should not be incorporated into standard postoperative management based on current evidence.

Tranexamic Acid in Liver Transplantation: Liver Transplant | June 2026

Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during liver transplantation remains controversial because of uncertain efficacy and concerns regarding thromboembolic complications. Why was this study needed?: Current evidence supporting routine prophylactic TXA use during OLT is limited and inconsistent. It is unclear whether prophylactic TXA reduces major perioperative bleeding and transfusion requirements. Safety concerns, particularly thromboembolic complications, have limited widespread adoption. Identifying patient subgroups most likely to benefit could enable a more personalized approach to antifibrinolytic therapy. Results: In this randomized, placebo-controlled trial, prophylactic TXA did not significantly reduce the overall incidence of major perioperative bleeding during liver transplantation. However, patients receiving TXA required fewer intraoperative red blood cell transfusions and had a shorter hospital stay. Importantly, benefits were more pronounced in lower-risk recipients, including those with low MELD 3.0 scores and Child–Pugh A cirrhosis. Rates of thromboembolic events and mortality were comparable between the TXA and placebo groups, supporting an acceptable safety profile. Clinical Impact: These findings do not support routine prophylactic TXA administration for all liver transplant recipients. Instead, TXA may offer meaningful clinical benefits in carefully selected lower-risk patients by reducing transfusion requirements and accelerating postoperative recovery without increasing thromboembolic risk. The study reinforces the need to move from universal prophylaxis toward individualized antifibrinolytic strategies based on patient risk profiles. Bottom Line: Routine prophylactic tranexamic acid is not justified for all liver transplant recipients, but selected lower-risk patients may benefit through reduced blood transfusion requirements and shorter hospitalization without compromising safety. Larger trials are needed to define patient groups most likely to benefit.

Whole-Organ Donor Liver Assessment Using PS-OCT: Science Translational Medicine | July 2026

Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This study evaluated polarization-sensitive optical coherence tomography (PS-OCT), a noninvasive imaging technique, for comprehensive whole-organ donor liver assessment. Why was this study needed? Liver biopsy samples only a tiny fraction of the donor liver and may overlook heterogeneous disease. Better methods are needed to accurately assess extended-criteria donor livers. Inaccurate assessment can lead to unnecessary organ discard or transplantation of poor-quality grafts. Whole-organ, noninvasive viability assessment has remained an unmet need. Artificial intelligence may improve interpretation of advanced imaging data. Results: PS-OCT accurately assessed steatosis, fibrosis, inflammation, and necrosis across the entire donor liver, showing excellent agreement with conventional histopathology. PS-OCT findings closely correlated with liver function during normothermic machine perfusion and with early post-transplant clinical outcomes, supporting its clinical relevance. By providing rapid, noninvasive whole-organ assessment, PS-OCT has the potential to reduce unnecessary organ discard while improving donor liver selection. Clinical Impact: This study represents a major advance in donor liver evaluation. PS-OCT combines high-resolution imaging with artificial intelligence to assess the entire liver rather than a small biopsy sample, potentially improving transplant decision-making and expanding the usable donor pool. Bottom Line: PS-OCT may redefine donor liver viability assessment. By providing accurate, noninvasive, whole-organ evaluation that correlates with graft function and transplant outcomes, it has the potential to reduce organ discard and safely expand liver transplantation.

Personalizing Antifibrinolytic Use in Liver Transplantation : Liver Transpl | Jul 2026

Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant practices and improved understanding of coagulation have prompted re-evaluation of routine prophylactic antifibrinolytic therapy. Problem Statement: Historically, antifibrinolytics were frequently administered empirically to liver transplant recipients because of the perceived high risk of hyperfibrinolysis. However, not all patients develop clinically significant fibrinolysis, raising concerns about unnecessary treatment, thrombotic complications, and indiscriminate use of these agents. The challenge is identifying which patients are most likely to benefit from targeted antifibrinolytic therapy. Summary: This editorial discusses the transition from routine empirical antifibrinolytic administration toward a personalized approach in liver transplantation. The author highlights that contemporary perioperative management, including improved surgical techniques, restrictive transfusion practices, and widespread use of viscoelastic coagulation monitoring, has substantially changed the bleeding profile of liver transplantation. As a result, universal prophylactic antifibrinolytic therapy may no longer be appropriate for all recipients. Instead, individualized treatment based on patient-specific bleeding risk, intraoperative coagulation status, and real-time assessment of fibrinolysis is increasingly favored. Viscoelastic testing offers an opportunity to identify clinically significant hyperfibrinolysis and guide targeted administration of antifibrinolytic agents, potentially maximizing benefit while minimizing unnecessary drug exposure and thrombotic risk. The editorial emphasizes that precision-based hemostatic management aligns with the broader movement toward personalized perioperative medicine. Future research should focus on refining risk stratification models, validating biomarker- and viscoelastic-guided treatment algorithms, and defining the subgroup of liver transplant recipients who derive the greatest benefit from antifibrinolytic therapy. Overall, the article argues that the era of routine empirical prophylaxis is giving way to individualized, evidence-based coagulation management, with the goal of optimizing patient safety while preserving the hemostatic advantages of antifibrinolytic treatment in liver transplantation.

Integrating LDLT into Modern Liver Transplant Programs: Liver Transplantation | June 2026

Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement deceased donor transplantation to expand access and improve patient outcomes. Why was this article needed? Many countries continue to face a shortage of deceased donor organs. Although LDLT is an established procedure with excellent outcomes, its adoption remains limited in many adult transplant programs because of logistical, ethical, and perceived clinical barriers. What did the article show? LDLT is an effective strategy to reduce the gap between organ demand and supply. It can shorten waiting times and reduce waitlist mortality, particularly for patients with advanced liver disease and selected liver cancers. Successful LDLT requires careful donor selection, rigorous recipient evaluation, and experienced multidisciplinary transplant teams. Donor safety remains the highest priority, requiring comprehensive medical, surgical, and psychological assessment. Ethical principles, informed consent, and independent donor advocacy are fundamental to every LDLT program. Countries with established deceased donor programs can further improve transplant access by incorporating LDLT into routine practice. Clinical Impact: Living donor liver transplantation should be viewed as a complementary, rather than competing, strategy to deceased donor transplantation. Expanding LDLT programs can increase transplant opportunities while maintaining high standards of donor safety and recipient outcomes. Take-Home Message: Living donor liver transplantation offers a sustainable solution to the growing shortage of donor organs. With appropriate expertise, ethical safeguards, and multidisciplinary care, LDLT can significantly expand access to life-saving liver transplantation while preserving donor safety.

Post-Transplant Management in Pediatric LT: Liver Transplantation | June 2026

Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care from transplantation through transition to adult services. Why was this guideline needed? * Advances in surgical techniques and intensive care have improved survival. * Long-term complications of immunosuppression remain a major concern. * Infection prevention and vaccination strategies have evolved. * Greater emphasis is now placed on nutrition, growth, development, and psychosocial well-being. * Standardised transition from pediatric to adult care is increasingly recognised as essential. Key Recommendations: Use individualized immunosuppression with the lowest effective dose to minimize long-term toxicity. Monitor closely for acute and chronic graft rejection through regular clinical and laboratory surveillance. Prevent infections with appropriate antimicrobial prophylaxis and timely immunization. Optimize nutrition early after transplantation to support normal growth and neurodevelopment. Regularly monitor renal function, cardiovascular risk factors, bone health, and metabolic complications. Screen for post-transplant lymphoproliferative disorder (PTLD) and other malignancies in high-risk patients. Assess developmental, cognitive, behavioral, and mental health outcomes during long-term follow-up. Promote medication adherence through patient and family education. Use a multidisciplinary team involving hepatologists, transplant surgeons, dietitians, psychologists, pharmacists, nurses, and social workers. Initiate structured transition planning during adolescence to ensure successful transfer to adult transplant services. Provide lifelong surveillance for graft function and late post-transplant complications. Clinical Impact: The updated guideline emphasises that successful pediatric liver transplantation extends beyond graft survival. Comprehensive multidisciplinary care, minimisation of immunosuppression-related toxicity, infection prevention, developmental support, and planned transition to adult care are essential for optimising lifelong outcomes. Take-Home Message: Modern pediatric liver transplantation focuses not only on preserving the liver graft but also on ensuring healthy growth, normal development, fewer treatment-related complications, and a smooth transition into adult care through coordinated multidisciplinary follow-up.

IBAT Inhibitor Relieves Refractory ICP After Liver Transplant : Liver Transpl | Jun 2026

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder characterized by severe pruritus and elevated bile acids, carrying risks for both maternal well-being and fetal outcomes. Management can be particularly challenging in patients with underlying cholestatic liver diseases, even after liver transplantation. Therapeutic options for refractory ICP remain limited when conventional treatment fails to adequately control symptoms and bile acid levels. Problem Statement: Women with a history of cholestatic disorders such as Alagille syndrome may remain susceptible to severe cholestatic complications during pregnancy despite successful liver transplantation. Refractory ICP can lead to debilitating pruritus and increased obstetric risk, highlighting the need for effective alternative therapies when standard treatments prove insufficient. Summary: This report describes the use of an ileal bile acid transporter (IBAT) inhibitor in a liver-transplanted woman with Alagille syndrome who developed refractory intrahepatic cholestasis of pregnancy. The case highlights the persistent vulnerability to cholestatic dysfunction that may remain despite transplantation, particularly under the physiological stress of pregnancy. Conventional therapeutic measures were insufficient to adequately control the patient's cholestatic symptoms, prompting consideration of an IBAT inhibitor. By reducing enterohepatic bile acid recirculation, IBAT inhibition offers a mechanistically targeted approach to lowering systemic bile acid burden and alleviating cholestatic symptoms. The reported experience suggests that this strategy may provide meaningful symptomatic and biochemical improvement in highly selected patients with difficult-to-manage ICP. Beyond its immediate clinical relevance, the case raises important questions regarding the potential role of IBAT inhibitors in pregnancy-associated cholestatic disorders, particularly among women with underlying genetic cholestatic diseases or prior liver transplantation. Although conclusions are necessarily limited by the single-patient nature of the report, the findings highlight a promising therapeutic avenue in an area where treatment options remain scarce. This case contributes to the emerging evidence supporting bile acid–targeted therapies and may stimulate future studies evaluating the safety and efficacy of IBAT inhibitors in severe or refractory ICP.

Post-Transplant Infections Drive Early Readmissions : Liver Transpl | Apr 2026

Introduction: Hospital readmission within 30 days of liver transplantation is a common and costly event that reflects early postoperative morbidity and is increasingly used as a quality metric in transplant care. Early readmissions place substantial burdens on patients and healthcare systems and have been associated with worse long-term outcomes. However, predictors of readmission have varied across studies, limiting the development of effective preventive strategies. Problem Statement: Most previous studies examining post-transplant readmissions have been limited by single-center experience or administrative datasets, making it difficult to identify consistent and actionable risk factors. Understanding the causes and predictors of early readmission is essential for improving post-transplant care and reducing avoidable healthcare utilization. Summary: Using the national TransQIP registry, this study evaluated patterns and determinants of unplanned 30-day readmission after deceased donor liver transplantation. The investigators found that early readmission was common, affecting more than two-fifths of transplant recipients. Most readmissions were relatively short and were not primarily driven by procedural complications, suggesting that medical issues remain the dominant cause of rehospitalization during the early post-transplant period. The most important finding was the strong association between post-discharge infectious complications and readmission risk. Organ-space surgical site infections emerged as the strongest predictor, followed by sepsis and urinary tract infections. These observations highlight infection prevention, early detection, and prompt outpatient management as critical targets for reducing readmissions after liver transplantation. In contrast, better pre-existing functional status was independently associated with a lower likelihood of readmission, emphasizing the importance of patient conditioning and functional recovery. The study also identified distinct risk profiles for different infection types, suggesting opportunities for more personalized post-discharge monitoring strategies. Overall, these findings indicate that many early readmissions may be preventable through focused infection surveillance, optimized discharge planning, and enhanced outpatient follow-up. The results provide important national-level evidence supporting targeted interventions aimed at reducing infectious complications and improving early outcomes after liver transplantation.

Frailty at 1 Year Predicts Long-Term Mortality After Liver Transplant : Liver Transpl | June 2026

Introduction: Frailty is increasingly recognized as a key determinant of outcomes in patients with advanced liver disease and has become an important component of liver transplant evaluation. Although many patients experience functional recovery after liver transplantation, a subset remain frail or develop new frailty during the post-transplant period. The long-term consequences of persistent or newly developed frailty after transplantation have not been well defined. Problem Statement: Most studies have focused on pre-transplant frailty, yet little is known about the prognostic significance of frailty after transplantation. Identifying whether post-transplant frailty influences long-term survival and quality of life could help guide follow-up strategies and inform interventions aimed at improving outcomes in liver transplant recipients. Summary: This multicenter analysis from the Functional Assessment in Liver Transplantation (FrAILT) Study demonstrates that frailty one year after liver transplantation is a powerful predictor of long-term outcomes. Approximately one in eight transplant recipients remained frail at one year, with frailty occurring more commonly among patients with metabolic dysfunction–associated steatotic liver disease, diabetes, prior frailty, and certain vascular comorbidities. Importantly, frailty at one year was associated with substantially higher long-term mortality and significantly poorer physical health-related quality of life. Even after accounting for other clinical factors, post-transplant frailty remained an independent predictor of adverse outcomes. Particularly noteworthy was the observation that patients who transitioned from a non-frail state before transplantation to a frail state one year later experienced the greatest increase in mortality risk. These findings challenge the assumption that successful transplantation alone eliminates the prognostic impact of frailty and suggest that functional recovery should be considered a major post-transplant outcome. The study highlights the first year after liver transplantation as a critical window for ongoing frailty assessment and intervention. Structured rehabilitation, nutritional optimization, physical activity programs, and targeted management of metabolic comorbidities may represent important opportunities to improve long-term survival and quality of life. Overall, the findings support incorporating routine frailty assessment into post-transplant care and emphasize frailty as a modifiable determinant of long-term transplant success.

GLP-1RAs Aid Weight Control After Liver Transplant : Liver Transpl | June 2026

Introduction: Weight gain and metabolic dysfunction are increasingly recognized as major challenges after liver transplantation. Obesity, diabetes, dyslipidemia, and metabolic dysfunction–associated steatotic liver disease can adversely affect graft health, increase cardiovascular risk, and compromise long-term survival. As glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial metabolic benefits in the general population, there is growing interest in their use among liver transplant recipients. However, concerns regarding safety, drug interactions, graft function, and immunosuppression have limited widespread adoption. Problem Statement: Evidence supporting the use of GLP-1RAs after liver transplantation remains limited, with uncertainty regarding their impact on graft outcomes, rejection risk, immunosuppressant levels, and cardiovascular safety. Robust real-world data are needed to determine whether these agents can effectively manage post-transplant weight gain without compromising allograft function. Summary: This multicenter international study evaluated the safety and effectiveness of GLP-1RAs in adult liver transplant recipients and provides reassuring evidence supporting their use in post-transplant metabolic management. Treatment with GLP-1RAs resulted in meaningful reductions in body weight, body mass index, and glycemic parameters, with additional modest improvements in lipid profiles. Importantly, these benefits were achieved without evidence of adverse effects on liver graft function, kidney function, or immunosuppressive drug levels. Matched analyses further confirmed superior weight loss and glycemic control among GLP-1RA users compared with non-users. Notably, there was no increased risk of allograft dysfunction, acute cellular rejection, or major adverse cardiovascular events. Semaglutide was the most commonly prescribed agent, reflecting current clinical practice patterns. These findings are particularly relevant as metabolic complications have emerged as a major determinant of long-term outcomes after transplantation. The study suggests that GLP-1RAs may offer a valuable therapeutic strategy for addressing post-transplant obesity and diabetes while maintaining graft safety. Although the observed weight loss was moderate and treatment doses were relatively low, the overall safety profile was highly encouraging. Prospective randomized trials are now needed to define optimal dosing strategies, long-term efficacy, and their potential role in preventing post-transplant metabolic and cardiovascular complications.

Redefining Early Allograft Dysfunction in LDLT : Liver Transpl | Jun 2026

Introduction: Early allograft dysfunction (EAD) remains one of the most important early indicators of graft performance after liver transplantation. Traditionally, EAD has been defined using biochemical parameters developed largely from deceased donor liver transplantation populations. However, living donor liver transplantation (LDLT) presents unique physiological and surgical characteristics, including smaller graft volumes, regenerative dynamics, and distinct perioperative factors, which may limit the applicability of conventional EAD definitions. Problem Statement: Current EAD models may not accurately reflect graft function or predict outcomes in LDLT recipients. Reliance on static biochemical thresholds can oversimplify the complex and evolving process of graft recovery, potentially leading to inaccurate risk stratification and delayed recognition of clinically significant dysfunction. There is an increasing need for more precise, individualized, and clinically meaningful approaches tailored specifically to LDLT. Summary: This editorial highlights the need to move beyond traditional definitions of EAD and adopt a more adaptive framework for assessing graft function following LDLT. The authors emphasize that graft recovery is a dynamic process influenced by donor characteristics, graft size, recipient factors, surgical complexity, and postoperative regenerative capacity. Rather than depending solely on fixed laboratory cut-offs, future models should incorporate longitudinal clinical and biochemical trends to better capture the evolving nature of graft performance. The article also underscores the growing potential of artificial intelligence and machine-learning technologies to integrate large volumes of perioperative and postoperative data, enabling more accurate prediction of graft dysfunction and patient outcomes. Such data-driven approaches could facilitate earlier intervention, personalized monitoring, and improved clinical decision-making. As LDLT continues to expand globally, the development of graft-specific and AI-enabled assessment tools may represent a significant step toward precision transplantation, offering a more nuanced understanding of early graft recovery and ultimately improving transplant outcomes.

Bucharest Consensus: Ethical Standards for Controlled DCDD: Transplant International | June 2026

* Controlled donation after circulatory determination of death is becoming an increasingly important pathway to expand deceased organ donation worldwide. * This ESOT Bucharest international consensus provides practical, ethical, and operational standards for adult controlled DCDD programs. * The recommendations were developed using a Delphi process involving 37 experts from 15 countries, covering intensive care, transplant surgery, donation coordination, ethics, and law. * The central principle is that decisions about withdrawal of life-sustaining measures must remain completely separate from decisions about organ donation. * A robust legal framework is essential before starting or expanding controlled DCDD programs, including clear rules for death determination, consent, donation authorization, and ante-mortem interventions. * Public and professional education is necessary because controlled DCDD differs from donation after neurological determination of death and may be poorly understood. * Potential donors should be identified early as part of routine end-of-life care, and referral triggers should be built into ICU and emergency care pathways. * Treating clinicians should not unilaterally exclude patients from donation; suitability assessment should involve donation professionals and transplant teams when needed. * Prediction of time to death after withdrawal of life support is imprecise, so suitability should not rely on a single scoring tool or individual clinician judgement alone. * Communication with families should be sensitive, staged, and preferably led by trained donation professionals who are not directly responsible for the patient’s clinical care. * Families should first understand that death is expected and that withdrawal of life-sustaining measures has been decided before donation is discussed. * Patient comfort, dignity, sedation, analgesia, and family presence during withdrawal of life support must remain central and should never be compromised for donation success. * The withdrawal process and comfort care should be managed by the treating clinical team, not by donation or transplant personnel. * Ante-mortem interventions may be considered when legally permitted, clinically justified, and aligned with the patient’s values or donation goals. * The benefits of ante-mortem interventions should be balanced against their invasiveness, discomfort, risk, and potential impact on the end-of-life experience. * The consensus emphasizes that donation can serve the patient’s values when donation was known or likely to be important to them, but this must never override comfort and dignity. * Programs should collect data on missed opportunities, failed donation attempts, and logistical barriers to improve future controlled DCDD pathways. * The report highlights the need for research into ante-mortem interventions, prediction of time to death after withdrawal, and best models for family communication. * Controlled DCDD should be developed through national protocols adapted to local legal, cultural, clinical, and logistical realities. Bottom line: The Bucharest ESOT consensus establishes controlled DCDD as an ethically acceptable and clinically important donation pathway, provided that end-of-life care remains patient-centered, donation decisions are clearly separated from withdrawal decisions, and ante-mortem interventions are carefully justified and transparently discussed.

HOPE Reduces Early Liver Graft Dysfunction : JAMA Surg | May 2026

Introduction: Introduction: Liver transplantation increasingly relies on extended-criteria donor (ECD) and donation-after-circulatory-death (DCD) grafts to address organ shortages. However, these grafts are more susceptible to ischemia-reperfusion injury, which contributes to early allograft dysfunction (EAD), prolonged hospitalization, biliary complications, and inferior post-transplant outcomes. Hypothermic oxygenated perfusion (HOPE) has emerged as a promising preservation strategy that restores mitochondrial function and reduces reperfusion injury before implantation. Problem Statement: Problem Statement: Although European studies have demonstrated benefits of HOPE, evidence supporting its effectiveness in a multicenter US transplant population using higher-risk donor livers has remained limited. Whether portal-venous HOPE can meaningfully improve graft function and clinical outcomes compared with conventional static cold storage (SCS) required prospective randomized evaluation. Summary: Summary: The Bridge to HOPE Trial was a multicenter randomized clinical trial conducted across 15 US liver transplant centers, enrolling 219 recipients of extended-criteria donor livers, including both donation-after-brain-death (DBD) and DCD grafts. Patients were randomized to receive either conventional static cold storage alone or portal-venous hypothermic oxygenated perfusion following transport and before implantation. The primary endpoint was early allograft dysfunction. HOPE significantly reduced EAD compared with static cold storage alone, occurring in 20.2% of recipients versus 37.3% in the control group. This represents a clinically meaningful reduction in early graft injury and demonstrates the capacity of oxygenated machine perfusion to improve immediate graft performance. Recipients receiving HOPE also achieved significantly better Model for Early Allograft Function (MEAF) scores, indicating superior early hepatic recovery after transplantation. Furthermore, HOPE was associated with a shorter hospital stay, suggesting faster postoperative recovery and reduced healthcare utilization. Importantly, the intervention was safe and easily integrated into routine transplant workflows. One-year patient survival and graft survival were excellent in both groups and did not significantly differ, reflecting the overall high success rates of contemporary liver transplantation. Although rates of non-anastomotic biliary strictures were not significantly different, post hoc analyses suggested fewer cases of graft loss related to biliary complications in the HOPE group. Major postoperative complications were also numerically lower among HOPE recipients. The biological rationale for HOPE lies in its ability to oxygenate the graft under hypothermic conditions before reperfusion. This process replenishes mitochondrial energy stores, reduces oxidative stress, limits inflammatory activation, and minimizes ischemia-reperfusion injury. These mechanisms are particularly important for marginal donor grafts, where preservation injury contributes substantially to early dysfunction. The study is notable because it evaluated a pragmatic “back-to-base” preservation strategy that can be implemented without requiring continuous machine perfusion during transport. This makes adoption more feasible for transplant programs compared with more complex normothermic perfusion systems. Overall, this landmark randomized trial demonstrates that portal-venous HOPE significantly reduces early allograft dysfunction, improves early graft function, and shortens hospital stay in recipients of extended-risk liver grafts. These findings support HOPE as an effective and practical preservation strategy that may improve outcomes as transplant programs increasingly utilize higher-risk donor organs.

Preemptive Anti-Craving Therapy May Reduce Post-Transplant Alcohol Relapse : Liver Transpl | May 2026

Introduction Alcohol-Associated Liver Disease has become one of the leading indications for Liver Transplantation worldwide. Although transplantation provides excellent survival benefit, post-transplant alcohol relapse remains a major concern because it can contribute to graft injury, recurrent liver disease, cardiovascular complications and reduced long-term survival. Strategies to prevent relapse after transplantation remain incompletely standardized, particularly among patients identified as high risk for recurrent alcohol use. Problem Statement Evidence supporting proactive pharmacologic anti-craving interventions after liver transplantation is limited, and optimal relapse-prevention strategies in high-risk transplant recipients remain poorly defined. Summary This rapid communication evaluated the impact of preemptive anti-craving therapy on post-transplant alcohol relapse among high-risk liver transplant recipients. The study addresses a highly relevant and evolving area within transplant hepatology, where the focus is increasingly shifting from rigid pretransplant abstinence rules toward structured longitudinal addiction management. The central finding was that early implementation of anti-craving pharmacotherapy appeared to reduce rates of alcohol relapse after transplantation in individuals considered at elevated relapse risk. Although details regarding specific agents and long-term relapse severity were limited in the brief report format, the findings support the growing concept that alcohol use disorder should be managed as a chronic relapsing neurobehavioral disease requiring ongoing therapeutic intervention rather than solely psychosocial monitoring. The study is clinically important because relapse risk after transplantation is multifactorial and cannot be reliably predicted by abstinence duration alone. Psychiatric comorbidity, prior relapse history, social instability and untreated craving pathways all contribute to recurrent alcohol use risk. Pharmacologic craving suppression may therefore provide an additional biologic layer of protection during the vulnerable post-transplant recovery period. These findings align with broader shifts in addiction medicine emphasizing integrated multidisciplinary care models that combine transplant hepatology, psychiatry, behavioral therapy and medication-assisted treatment. Increasing evidence suggests that structured post-transplant addiction management may improve not only abstinence outcomes but also graft survival and overall quality of life. Potential anti-craving agents in this context may include medications such as Acamprosate, Naltrexone or baclofen-based approaches, although individual agent selection in transplant recipients requires careful consideration of hepatic metabolism, neuropsychiatric effects and drug interactions with immunosuppressive therapy. Importantly, the study also contributes to ongoing efforts to destigmatize alcohol-associated liver disease within transplantation. Demonstrating benefit from proactive relapse-prevention therapy reinforces the principle that relapse risk can be medically managed rather than viewed solely as a behavioral failure. The work further supports the movement toward precision psychosocial risk stratification in transplant hepatology. Rather than universally applying identical monitoring strategies, high-risk individuals may benefit from intensified multidisciplinary follow-up and early pharmacologic intervention. However, larger prospective studies remain necessary to define optimal timing, duration and choice of anti-craving therapies after transplantation. Long-term effects on sustained abstinence, graft outcomes, survival and quality of life also require further validation. Overall, this study suggests that preemptive anti-craving pharmacotherapy may reduce post-transplant alcohol relapse among high-risk liver transplant recipients. The findings support a proactive addiction medicine framework within transplant hepatology and highlight the importance of integrating pharmacologic relapse prevention into comprehensive post-transplant care pathways.

ACLF Definitions: JCTH | May 2026

- Acute-on-chronic liver failure (ACLF) is a severe syndrome characterized by acute decompensation, organ failure, and high short-term mortality in patients with cirrhosis. However, ACLF lacks a universally accepted definition. Multiple frameworks exist globally, leading to inconsistencies in diagnosis, risk stratification, clinical trials, and regulatory pathways. - This multinational study compared the newly proposed 2025 consensus ACLF definition with the outcome-based A-TANGO classification, which was designed using mortality-calibrated organ failure thresholds. - The major challenge in ACLF is balancing harmonization with clinical accuracy. Broader consensus definitions may improve standardization but risk missing clinically important patients if sensitivity declines. The critical question addressed in this study was: Does the newer consensus framework accurately identify high-risk ACLF patients, or does it underdiagnose clinically meaningful disease compared with outcome-based models? - This large multinational study involving nearly 5,000 patients from India and China demonstrated major differences between the two ACLF frameworks. The A-TANGO model identified substantially more patients as ACLF compared with the consensus definition. Importantly, many patients labeled “non-ACLF” by the consensus criteria but classified as ACLF by A-TANGO had significant short-term mortality, with 28-day mortality ranging from 18%–27%. A-TANGO consistently showed higher sensitivity for predicting mortality, whereas the consensus definition was more specific but captured a smaller and more advanced liver-centered phenotype. The study also demonstrated that the consensus “non-ACLF” group was not truly low risk. A-TANGO further stratified these patients into progressively higher mortality groups, revealing hidden clinical heterogeneity. Overall, the findings suggest that A-TANGO may identify patients earlier in the disease trajectory, potentially at a stage where intervention remains possible. In contrast, the consensus framework appears to diagnose ACLF later, potentially missing high-risk patients with evolving multi-organ dysfunction. This work has major implications for clinical care, ICU triage, transplant decisions, and future ACLF trial design.

Ferroptosis Blockade Improves Liver and Lung Graft Function : Cell | May 2026

Introduction Ischemia–reperfusion injury (IRI) remains a major barrier in organ transplantation and contributes significantly to graft dysfunction, early allograft injury and organ discard. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently emerged as a key mechanism underlying tissue injury during ischemia and reperfusion. Problem Statement Despite increasing recognition of ferroptosis in transplant-associated injury, no clinically applicable therapies currently target this pathway. Existing ferroptosis inhibitors have been limited by poor pharmacokinetics and inadequate translational potential, while the precise temporal dynamics of lipid peroxidation during human transplantation remain incompletely characterized. Summary This landmark translational study identifies ferroptosis as a major therapeutic target in transplantation and introduces FXT-001 as a first-in-class drug-like ferroptosis inhibitor with promising clinical applicability. The investigators demonstrated that lipid peroxidation rapidly peaks within the first hour after graft reperfusion in human liver transplantation and correlates with severe ischemia–reperfusion injury. FXT-001 combines radical-trapping antioxidant activity with iron-binding capacity, enabling dual suppression of lipid peroxidation and ferroptotic cell death. Mechanistic studies showed preferential localization of FXT-001 within mitochondria and endolysosomal compartments, where it modulates subcellular iron handling and prevents membrane lipid radical propagation. In clinically relevant porcine liver donation-after-circulatory-death models, FXT-001 significantly reduced hepatocellular injury markers, improved glucose metabolism and preserved choleretic function during ex situ reperfusion. Parallel experiments in porcine and declined human donor lungs demonstrated reduced edema formation, lower extravascular lung water and improved graft compliance following ferroptosis inhibition. Importantly, the study also developed next-generation analogues, FXT-002 and FXT-003, with improved pharmacokinetic and safety profiles while retaining potent ferroptosis inhibition. The findings position ferroptosis inhibition as a potentially transformative strategy not only in transplantation but also across a broad spectrum of ischemia-associated conditions including myocardial infarction, stroke and vascular surgery. Overall, this work provides one of the strongest translational demonstrations to date that pharmacologic ferroptosis blockade can meaningfully improve organ preservation and graft function in human-relevant systems.

Living-Donor Liver Transplantation Improves Survival in Unresectable Colorectal Liver Metastases : Liver Transpl | May 2026

Introduction Colorectal liver metastases remain a major cause of cancer-related mortality, and curative treatment is traditionally limited to patients eligible for hepatic resection. However, many patients present with technically unresectable liver-only disease despite favorable tumor biology and good response to systemic chemotherapy. In recent years, liver transplantation has re-emerged as a potential treatment strategy for carefully selected patients with unresectable colorectal liver metastases. Problem Statement Although promising survival outcomes have been reported with liver transplantation in selected metastatic colorectal cancer patients, widespread adoption remains limited by donor organ scarcity, concerns regarding recurrence and uncertainty regarding long-term oncologic benefit compared with modern systemic therapy alone. Summary This study demonstrates that liver transplantation using a living-donor RAPID approach provides a substantial survival advantage over chemotherapy alone in carefully selected patients with unresectable colorectal liver metastases. Eligible patients had liver-confined disease with stable disease or tumor regression following systemic therapy, reflecting strict biologic selection criteria. Patients undergoing transplantation achieved markedly superior long-term survival compared with patients who could not proceed because of donor unavailability, supporting transplantation as a potentially curative strategy in highly selected metastatic colorectal cancer. The RAPID technique, involving staged partial liver transplantation with delayed hepatectomy, also highlights an innovative approach to expanding transplant feasibility while minimizing donor burden. Although recurrence remained common after transplantation, recurrent disease was often compatible with prolonged post-recurrence survival, suggesting that transplantation may meaningfully alter disease trajectory even when recurrence occurs. Importantly, the study reinforces the growing concept that tumor biology and treatment responsiveness may be more relevant than traditional metastatic classification alone when considering advanced surgical or transplant-based oncologic strategies. Overall, these findings strengthen the evolving role of liver transplantation in transplant oncology and support living-donor transplantation as a feasible pathway to expand access for selected patients with unresectable colorectal liver metastases.

ABO-Incompatible Liver Transplantation Shows Comparable Outcomes in Children | Liver Transplantation

Introduction Liver transplantation is the definitive treatment for children with end-stage liver disease, yet waitlist mortality remains a major challenge, particularly in infants and critically ill children with limited donor availability. ABO-incompatible (ABO-I) liver transplantation has emerged as a potential strategy to expand the donor pool, although concerns regarding antibody-mediated rejection and vascular complications have historically limited its broader use. Problem Statement Despite increasing clinical experience, uncertainty persists regarding the long-term safety and efficacy of ABO-I liver transplantation in pediatric recipients. Variability in institutional protocols, including desensitization strategies and immunosuppression approaches, has further complicated the development of standardized practice recommendations. Summary This large multicenter analysis from the SPLIT registry demonstrates that pediatric recipients of ABO-incompatible liver transplantation achieve graft and patient survival outcomes comparable to those receiving ABO-compatible grafts. Although ABO-I recipients were generally more critically ill at the time of transplantation—with greater need for intensive care, ventilatory support and parenteral nutrition—three-year graft and patient survival did not differ significantly between the two groups. These findings support the growing view that ABO-I transplantation can safely expand donor access in pediatric liver transplantation, particularly for high-risk infants facing prolonged wait times. Importantly, younger children undergoing ABO-I transplantation demonstrated a higher incidence of early portal vein thrombosis, highlighting the need for careful vascular surveillance and optimized perioperative management in this subgroup. The accompanying center-level survey also revealed marked heterogeneity in eligibility criteria, desensitization practices and immunosuppressive protocols across transplant programs, emphasizing the absence of standardized approaches. Overall, this study provides important real-world evidence supporting broader implementation of ABO-I pediatric liver transplantation while underscoring the need for prospective studies to refine protocols and improve consistency across centers.

Cardiovascular Disease Remains a Major Threat After Kidney and Liver Transplantation Heart | 2026

Introduction Kidney and liver transplantation substantially improve survival and quality of life in patients with end-stage organ disease. However, cardiovascular disease (CVD) remains a leading cause of long-term morbidity and premature mortality after transplantation. Despite successful graft function, transplant recipients continue to face a substantial burden of cardiovascular complications that extends well beyond the peri-transplant period. Problem Statement Although transplantation reduces mortality compared with dialysis or untreated end-stage liver disease, it does not eliminate cardiovascular risk. Kidney and liver transplant recipients remain vulnerable to a broad spectrum of cardiac disorders, including coronary artery disease, heart failure, arrhythmias, valvular disease and pulmonary hypertension. This persistent risk reflects the combined effects of pre-existing cardiometabolic disease, transplant-related metabolic injury and chronic exposure to immunosuppressive therapy, creating a complex and often under-recognized cardiovascular burden. Summary This review highlights the persistent and multifactorial cardiovascular risk faced by kidney and liver transplant recipients, emphasizing that transplantation should be viewed as a transition to chronic cardiovascular risk management rather than risk resolution. The authors describe how pre-transplant vascular disease is compounded after transplantation by weight gain, dyslipidaemia, diabetes, hypertension and immunosuppression-related metabolic toxicity, resulting in sustained cardiovascular vulnerability. Importantly, this risk spans multiple cardiac phenotypes, including ischemic heart disease, heart failure, arrhythmias, valvular dysfunction and pulmonary vascular disease, each requiring organ-specific clinical consideration. The review underscores that cardiovascular surveillance in transplant recipients must extend beyond traditional risk assessment and incorporate longitudinal, multidisciplinary care tailored to graft type and metabolic profile. A central message is that long-term transplant success depends not only on graft survival, but also on proactive cardiovascular prevention, early recognition of evolving cardiac disease and coordinated management across transplant, cardiology and metabolic care teams.

Deceased Donor Liver Transplantation Increases Risk of Biliary Cast Syndrome Liver Transplantation | April 2026

Introduction Biliary cast syndrome (BCS) is an uncommon but clinically significant biliary complication after liver transplantation, characterized by the formation of obstructive biliary debris within the graft biliary tree. It has traditionally been associated with ischemic biliary injury, biliary strictures, and hepatic artery compromise, and may contribute to recurrent cholangitis, graft dysfunction, and, in severe cases, graft loss. However, contemporary data defining its risk profile—particularly across living donor and deceased donor liver transplantation—remain limited. Problem Statement The determinants of BCS after liver transplantation are incompletely understood, especially whether the risk differs meaningfully between living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT). This distinction is clinically important because donor type influences ischemic exposure, biliary vulnerability, and postoperative management. Clarifying the major predictors of BCS and its long-term clinical impact may improve surveillance strategies and guide early intervention. Summary In this single-center retrospective study of 469 adult liver transplant recipients, BCS developed in 6.6% of patients. The risk was markedly higher after DDLT than LDLT, identifying deceased donor grafts as the strongest independent predictor of BCS. Additional major risk factors included biliary stricture, hepatic arterial complications, and older donor age, reinforcing the central role of ischemic and biliary injury in BCS pathogenesis. Despite its clinical relevance, BCS did not adversely affect long-term graft or overall survival when managed appropriately. Endoscopic intervention appeared effective in controlling disease progression and preserving outcomes, even in patients with established BCS. These findings highlight DDLT recipients as a higher-risk population requiring closer biliary surveillance and support early endoscopic management as a key strategy to maintain favorable long-term transplant outcomes.

Post-Transplant Liver Assessment: Liver Transplantation | April 2026

Introduction Liver transplantation has dramatically improved survival in patients with end-stage liver disease and hepatocellular carcinoma. However, long-term outcomes are often compromised by complications such as graft rejection, recurrent disease, or de novo liver pathology leading to fibrosis and cirrhosis. Traditionally, monitoring relies on invasive methods like liver biopsy, but increasing attention is being given to Non-invasive tests as safer alternatives. Problem Statement The role and optimal application of non-invasive tests in post-transplant liver assessment remain unclear and are not yet standardized in routine clinical practice. Summary This review emphasizes the emerging role of non-invasive tests in monitoring liver graft health after transplantation. NITs—including tools for assessing fibrosis, steatosis, and portal hypertension—have already transformed management in native liver disease, but their translation into the post-transplant setting is still evolving. The authors highlight that NITs can potentially detect early graft dysfunction, reducing the need for repeated biopsies and enabling closer, safer monitoring. However, interpretation in the transplant setting is more complex due to factors such as immunosuppression, vascular changes, and mixed etiologies of graft injury. A key takeaway is the need for contextual interpretation—NIT results should not be used in isolation but integrated with clinical, biochemical, and imaging data. Despite current limitations, NITs offer a promising pathway toward personalized, longitudinal graft surveillance, allowing earlier intervention and improved long-term outcomes. Overall, this review supports a gradual shift from invasive to non-invasive monitoring strategies in post-transplant care, while emphasizing the need for further validation and standardized protocols.

Hepatic Hypoxia in Donation After Circulatory Death (DCD): Liver Transplantation | February 2026

Introduction Donation after circulatory death (DCD) has emerged as an important strategy to expand the donor pool in liver transplantation. However, compared to brain-dead donors, DCD grafts are more vulnerable to hypoxic injury due to unavoidable periods of warm ischemia. A key concept is donor warm ischemic time (dWIT), particularly the functional dWIT, during which hepatic oxygen delivery becomes critically compromised. The liver has remarkable autoregulatory mechanisms—primarily the hepatic arterial buffer response and high oxygen extraction capacity—but these mechanisms fail beyond certain thresholds of hypoperfusion and hypoxia. This results in ischemia-reperfusion injury (IRI), the central driver of graft dysfunction and complications after transplantation. Problem Statement Despite increasing use of DCD grafts, there is poor understanding of the exact physiological thresholds of hepatic hypoxia and the lack of standardized definitions of functional warm ischemia time, leading to variability in graft selection, discard rates, and clinical outcomes. Summary This review provides a mechanistic framework linking hepatic physiology to DCD outcomes. The liver receives dual blood supply—75% from the portal vein and 25% from the hepatic artery—with intrinsic autoregulation maintaining oxygenation even with reduced flow. However, during DCD, progressive hypotension and hypoxemia eventually overwhelm these compensatory mechanisms. Functional dWIT—when oxygen delivery falls below critical thresholds—is the most relevant determinant of graft injury, yet remains inconsistently defined across centers. Hepatic injury primarily occurs during reperfusion rather than ischemia itself. During ischemia, the liver becomes metabolically primed, accumulating inflammatory mediators. Upon reperfusion, a cascade of sterile inflammation occurs involving neutrophils, Kupffer cells, cytokines, and endothelial dysfunction, leading to hepatocyte necrosis and microcirculatory failure. Clinical correlates from hypoxic hepatitis and congestive hepatopathy suggest that both hypoxia and congestion contribute to injury. Additional factors such as donor hemodynamic trajectory, oxygen saturation, cardiac function, and underlying liver quality (steatosis/fibrosis) further influence outcomes. Future directions include better physiological definition of functional dWIT, real-time monitoring of hepatic oxygenation, and use of emerging technologies such as machine perfusion to mitigate ischemia-reperfusion injury. This integrated physiological approach may reduce graft discard and improve outcomes in DCD liver transplantation.

Modified Cavo-Portal Hemi-Transposition in Adult LDLT: Annals of HPB Surgery | February 2026

Introduction Extensive porto-mesenteric thrombosis has traditionally been considered one of the most difficult situations in liver transplantation because adequate portal inflow is essential for graft regeneration and long-term function. In living donor liver transplantation, this challenge becomes even greater because the graft depends heavily on sufficient portal shear stress for recovery and growth. Although alternative inflow options such as reno-portal anastomosis, cavo-portal hemi-transposition, portal vein arterialization, and multivisceral transplantation exist, each has important technical and physiological limitations. Among these, cavo-portal hemi-transposition is well described in pediatric transplantation but remains rarely reported in adults, especially in living donor liver transplantation. Problem Statement In adult living donor liver transplantation, cavo-portal hemi-transposition is technically difficult because the right lobe graft portal vein is not naturally aligned with the inferior vena cava. This can lead to angulation, poor flow, thrombosis, persistent portal hypertension, and inadequate systemic venous drainage, making outcomes less favorable in adults than in pediatric patients. Summary This article describes an important technical modification of cavo-portal hemi-transposition in two adult living donor liver transplant recipients with diffuse porto-mesenteric thrombosis, one of whom also had Budd-Chiari syndrome. The key modification was to use the left renal vein–inferior vena cava junction as the site for inflow and to add a cryopreserved portal vein graft as an interposition conduit. This created a straighter alignment between the graft portal vein and the systemic venous inflow, while avoiding excessive mobilization of the vena cava and preserving collateral venous channels. The authors believe this improves portal inflow, reduces the risk of kinking and thrombosis, and helps maintain adequate inferior vena cava drainage. One patient had good long-term graft function after management of partial portal vein thrombosis with stenting, while the second patient died from fungal sepsis despite a patent reconstruction. Overall, the study suggests that this modified technique is a practical rescue option in highly selected adult living donor liver transplantation cases with diffuse splanchnic venous thrombosis, but it should be performed only in expert high-volume transplant centers.

Selective Splenectomy Guided by Graft-to-Spleen Volume Ratio in LDLT: Liver Transplantation | April 2026

Introduction Early allograft dysfunction (EAD) remains a major challenge after living donor liver transplantation (LDLT), often driven by portal hyperperfusion and small-for-size graft physiology. Splenectomy has been used to modulate portal flow, but its routine use is controversial due to surgical risks. The graft-to-spleen volume ratio (GSVR) has emerged as a potential physiological marker to better select patients who may benefit from splenectomy. Problem Statement There is no clear, objective criterion to guide selective splenectomy in LDLT. Empirical or routine splenectomy may expose patients to unnecessary risks, while omission in high-risk patients may lead to EAD, thrombocytopenia, ascites, and graft dysfunction. A reliable, reproducible strategy is needed to identify patients who truly benefit from splenic modulation. Summary This prospective study validated a GSVR-based selective splenectomy strategy in 141 LDLT recipients. Splenectomy was performed when GSVR ≤0.70 or in high-risk settings (ABO incompatibility, older donor, high portal pressure).

Neuroprotection in ALF: Journal of Hepatology | March 2026

Introduction Neuroprotection remains a central challenge in the management of acute liver failure, where cerebral oedema and intracranial hypertension are major drivers of mortality. Traditionally, invasive intracranial pressure monitoring has been used to guide management, but recent shifts in clinical practice suggest a move away from this approach. This evolving paradigm reflects a deeper understanding of the pathophysiology of brain injury in acute liver failure, where ammonia toxicity, systemic inflammation, and blood–brain barrier dysfunction act synergistically rather than independently. Summary This article highlights a significant transition in neuroprotective strategies in acute liver failure following evidence that declining use of invasive intracranial pressure monitoring has not adversely affected survival outcomes. The focus is shifting from reactive management of intracranial hypertension to proactive prevention of cerebral oedema. Blood ammonia is emphasised as a key early biomarker for identifying high-risk patients, although it is recognised as a downstream marker rather than the primary driver of injury. Increasing attention is being directed toward upstream mechanisms, particularly systemic inflammation and cytokine-mediated neurotoxicity, which may offer future therapeutic targets. The second major shift is toward non-invasive, multimodal neurological monitoring. Emerging tools such as transcranial Doppler, near-infrared spectroscopy, and continuous electroencephalography offer dynamic insights into cerebral perfusion, oxygenation, and neuronal activity, enabling a more comprehensive and individualised assessment of brain function without procedural risk. Finally, the reduction in invasive monitoring introduces a critical clinical challenge: determining irreversible brain injury and transplant eligibility. The author proposes a multimodal framework combining imaging, functional neurophysiology, and biomarkers to guide decision-making. This approach is essential to ensure appropriate use of liver transplantation while avoiding both futile interventions and missed opportunities for timely transplantation.

Post LT Immunosuppressive Strategies for PSC: Journal of Hepatology | March 2026

Introduction Primary sclerosing cholangitis is a unique indication for liver transplantation because long-term outcomes are influenced not only by graft survival, but also by the risks of acute cellular rejection, recurrent PSC, and complications related to associated inflammatory bowel disease. Although survival after transplantation is generally favorable, the ideal post-transplant immunosuppressive strategy remains uncertain. This international survey from the IPSCSG is important because it highlights how little standardization currently exists in the care of PSC patients after liver transplantation. Summary This survey of 31 transplant centers across Europe, the United States, and other regions showed marked heterogeneity in immunosuppressive practice after liver transplantation for PSC. Nearly half of centers reported using a more intensive immunosuppressive approach in PSC than in other transplant recipients, and basiliximab induction was routinely used by a similar proportion. Triple immunosuppression was common early after transplantation, but long-term practice varied substantially. Some centers tapered to tacrolimus monotherapy, most used dual therapy, and about one-quarter maintained triple therapy long term. Corticosteroid use also differed greatly, with most centers stopping prednisolone within the first year, while nearly one-third continued lifelong prednisolone. Importantly, these differences were seen even among high-volume transplant centers, suggesting that experience alone has not led to convergence in practice. Follow-up strategies also varied, including inconsistent use of imaging and protocol liver biopsies. The major message is that post-transplant care in PSC remains highly individualized and not evidence-based. This variation creates an important opportunity for comparative outcome studies to determine whether certain immunosuppressive strategies are associated with lower recurrence, better graft survival, or fewer long-term complications.

Transplant Timing in Perihilar Cholangiocarcinoma: Ann of Surgery, Feb. 2026

This large single-centre analysis evaluated whether earlier liver transplantation improves survival in patients with perihilar cholangiocarcinoma (pCCA) treated with standardised neoadjuvant therapy and transplant protocol. The key question: Does transplanting within 6 months of protocol registration improve outcomes? Study Overview 392 patients in the intention-to-treat cohort 256 underwent liver transplantation Median time to transplant/dropout: ~5.7 months Key Findings Shorter wait times (0–3 months) did NOT improve overall survival. Waiting longer (≥6 months) did not worsen intention-to-treat survival. Importantly, among transplanted patients: Waiting ≥6 months was associated with lower post-transplant mortality. Survival benefit became more pronounced beyond 9 months. Waiting time was not associated with increased residual tumour in the explant. Clinical Interpretation This study challenges the assumption that “earlier is better” for transplant in pCCA. A minimum 6-month waiting period may: Allow biological selection of favourable tumour behaviour Reduce post-transplant mortality Maintain overall survival in the broader cohort Take-Home Message for Hepatobiliary & Transplant Teams Transplantation within 6 months of registration does not enhance survival, and waiting ≥6 months may optimise outcomes without compromising overall patient survival. This reinforces the importance of disciplined protocol adherence and biological selection in pCCA transplant programs.

Managing Multiple Bile Ducts in LDLT- Liver Transplant Feb.26

Multiple bile ducts (MBDs) in living donor liver transplantation (LDLT) remain a major technical challenge, particularly in right lobe grafts. This large retrospective study analysed 1,780 microsurgical biliary reconstructions over 16 years to determine optimal reconstruction strategies and outcomes. Approximately 23% of grafts had multiple bile ducts. Overall, biliary complications were higher in MBD grafts compared with single-duct grafts (14.7% vs 11.2%), driven mainly by increased bile leak rates (6.1% vs 2.1%), while stricture rates were similar. Among adult LDLT recipients with right lobe grafts, 2-to-2 duct-to-duct reconstructions had the highest complication rate (16.6%). In contrast, 2-to-2 duct-to-jejunum anastomoses showed no biliary complications in this cohort. Overall, duct-to-duct reconstruction was associated with significantly higher biliary complications than duct-to-jejunum anastomosis (12.5% vs 2.6%). The study emphasises the importance of individualised surgical planning. Technical refinements—such as biliary stenting, ipsilateral duct alignment, figure-of-8 suturing at junctions, and centralisation techniques for size mismatch—may reduce complications. For transplant surgeons, the key message is that duct-to-jejunum reconstruction should be strongly considered in grafts with multiple bile ducts, particularly in complex 2-to-2 configurations, as it may lower leak risk and improve early biliary outcomes.

The Liver Transplant Comorbidity Index- Hepatology Feb.26

Frailty is a powerful predictor of outcomes after liver transplantation, but it cannot be used alone to determine transplant candidacy because many frail patients still achieve acceptable survival. This multicenter prospective study introduces the Liver Transplant Comorbidity Index (LTCI), a composite tool designed to better identify patients at higher risk of longer-term post–liver transplant mortality by integrating frailty with other key comorbidities. Using data from the Functional Assessment in Liver Transplantation (FrAILT) study across eight transplant centres, the investigators evaluated adults undergoing primary deceased-donor liver transplantation. Frailty was assessed using the Liver Frailty Index, and additional clinical variables were examined to determine their contribution to three-year posttransplant mortality. Through a combination of statistical rigor and clinical pragmatism, the final LTCI incorporated five readily available pretransplant factors: frailty, coronary artery disease, hepatocellular carcinoma, renal dysfunction, and diabetes. The LTCI effectively stratified patients into low-, moderate-, and high-risk groups with progressively worse posttransplant survival. Importantly, the index remained predictive even after accounting for donor-related factors, demonstrating that recipient comorbidity burden meaningfully influences outcomes beyond traditional transplant risk models. Clinically, the LTCI provides a balanced framework for transplant decision-making. Rather than excluding patients based on frailty alone, it contextualises frailty alongside other comorbidities, allowing clinicians to more accurately weigh transplant risks and benefits. This tool may help standardise candidate assessment, support shared decision-making, and promote equitable and evidence-based liver transplant selection.

Gut–liver–muscle axis -Front. Med. 2026

### The Gut–Liver–Muscle Axis: Overview and Key Insights The "gut-liver-muscle axis" is an emerging concept that highlights the interconnected relationship between gut microbiota, liver metabolism, and skeletal muscle health. This axis provides a framework to understand how disruptions in one organ system (e.g., the gut) can lead to systemic effects on the liver and skeletal muscles, particularly in the context of chronic liver diseases. Below is a detailed breakdown of the concept: --- ### 1. **What is the Gut–Liver–Muscle Axis?** The gut-liver-muscle axis is a physiological network that connects the gut, liver, and skeletal muscle through metabolic, immunological, and hormonal pathways. It emphasizes the role of gut microbiota in modulating liver function and skeletal muscle homeostasis, thereby influencing energy metabolism, protein synthesis, and inflammation. --- ### 2. **Role of Gut Microbiota in the Axis** - **Gut Dysbiosis**: Imbalances in gut microbiota, such as reduced microbial diversity, decreased beneficial bacteria, and increased pathogenic bacteria, play a central role in disrupting the gut-liver-muscle axis. - **Intestinal Barrier Dysfunction**: Gut barrier integrity is often weakened in chronic liver diseases, allowing bacterial products (e.g., lipopolysaccharides or LPS) to enter the portal circulation and trigger liver inflammation. - **Microbial Metabolites**: Key products of gut bacteria, such as short-chain fatty acids (SCFAs), bile acids, and amino acid metabolites, influence both liver and muscle metabolism. --- ### 3. **Liver's Role in the Axis** - **Energy Metabolism**: The liver is a critical organ for energy storage and nutrient metabolism. In chronic liver disease, impaired liver function disrupts glucose, lipid, and protein metabolism, contributing to malnutrition and muscle wasting. - **Inflammation**: Persistent liver inflammation due to gut-derived LPS and other microbial products exacerbates metabolic dysfunction and promotes muscle protein breakdown. - **Amino Acid Imbalances**: Liver dysfunction leads to impaired branched-chain amino acid (BCAA) utilization and increased aromatic amino acids (AAAs), which negatively affect muscle protein synthesis. --- ### 4. **Muscle's Role in the Axis** - **Sarcopenia**: Sarcopenia, or the loss of skeletal muscle mass and strength, is a hallmark of malnutrition in chronic liver disease. It is influenced by systemic inflammation, hyperammonemia, and energy metabolic dysfunction. - **Energy Deficits**: Reduced SCFA production and impaired nitrogen metabolism weaken muscle energy supply, contributing to muscle wasting. - **Hyperammonemia**: Elevated blood ammonia levels (common in liver cirrhosis) impair muscle protein synthesis and energy metabolism. --- ### 5. **Key Pathways in the Gut–Liver–Muscle Axis** - **Inflammatory Signaling**: Gut-derived LPS activates liver Kupffer cells, inducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) via NF-κB signaling. These cytokines promote muscle protein degradation and inhibit synthesis. - **Nitrogen Metabolism**: Dysbiosis leads to increased ammonia-producing bacteria, exacerbating hyperammonemia and nitrogen imbalance, which impair muscle function. - **SCFA Production**: SCFAs (e.g., butyrate, acetate, propionate) are crucial for energy metabolism. Reduced SCFA levels due to gut dysbiosis weaken muscle mitochondrial function and glycogen storage. - **Bile Acid Signaling**: Gut microbiota modulate bile acid metabolism, which influences liver lipid metabolism and systemic energy regulation. --- ### 6. **Chronic Liver Diseases and the Gut–Liver–Muscle Axis** Several liver diseases are closely associated with disruptions in the gut-liver-muscle axis: - **Non-Alcoholic Fatty Liver Disease (NAFLD)**: Gut dysbiosis contributes to insulin resistance, lipid metabolism disorders, and sarcopenic obesity in NAFLD. - **Alcoholic Liver Disease (ALD)**: Chronic alcohol consumption disrupts gut microbiota, weakens the gut barrier, and promotes liver inflammation and muscle wasting. - **Liver Cirrhosis**: Advanced cirrhosis is characterized by significant dysbiosis, hyperammonemia, and systemic inflammation, leading to severe sarcopenia. - **Viral Hepatitis and Autoimmune Liver Diseases**: Persistent inflammation and immune dysregulation in these conditions are exacerbated by gut microbiota imbalances. --- ### 7. **Therapeutic Implications of the Gut–Liver–Muscle Axis** Understanding the gut-liver-muscle axis has opened new avenues for therapeutic interventions: - **Probiotics/Prebiotics**: These can restore microbial balance, enhance SCFA production, and improve gut barrier function. - **Faecal Microbiota Transplantation (FMT)**: FMT has shown promise in reducing gut-derived inflammation, improving ammonia metabolism, and restoring gut-liver axis function. - **Nutritional Support**: Supplementing with branched-chain amino acids (BCAAs), dietary fiber, and polyunsaturated fatty acids (PUFAs) can improve muscle protein synthesis and energy metabolism. - **Integrated Approaches**: Combining microbiome-based therapies with nutritional and pharmacological interventions may offer a comprehensive strategy for managing liver disease-related malnutrition and sarcopenia. --- ### 8. **Future Directions** - **Multi-Omics Research**: Advanced tools like metagenomics, metabolomics, and proteomics will help identify specific microbial and metabolic signatures associated with liver disease and sarcopenia. - **Personalized Medicine**: Developing tailored microbiome interventions and nutritional therapies based on individual microbiota profiles. - **Dynamic Modeling**: Using artificial intelligence and computational models to predict disease progression and optimize treatment strategies for the gut-liver-muscle axis. --- ### Conclusion The gut-liver-muscle axis is a critical and interconnected pathway that plays a significant role in the development of malnutrition and sarcopenia in chronic liver diseases. Gut dysbiosis, liver dysfunction, and muscle wasting are interlinked through complex metabolic and inflammatory pathways. By targeting the gut microbiota and its metabolites, novel therapeutic strategies can be developed to improve the nutritional outcomes, muscle health, and overall prognosis of patients with liver diseases.

AASLD–AST Practice Guideline on Adult Liver Transplantation

The AASLD–AST (American Association for the Study of Liver Diseases and the American Society of Transplantation) Practice Guideline on Adult Liver Transplantation provides a comprehensive framework for the management of adult liver transplant recipients. This guideline encompasses key areas of pre-transplant, perioperative, and post-transplant care, focusing on optimizing outcomes and addressing complications. Below is a detailed overview of the guideline's principles based on the provided context: --- ### **1. Long-term Outcomes Beyond Graft Function** - **Focus Beyond Graft**: While graft survival is critical, long-term outcomes are more significantly influenced by non-graft-related medical and surgical complications. This underscores the importance of managing systemic health issues in liver transplant recipients. --- ### **2. Immunosuppression and its Impact** - **Chronic Immunosuppression**: Immunosuppressive medications, while essential to prevent graft rejection, contribute to complications such as: - **Metabolic dysfunction**: Including diabetes, hypertension, and dyslipidemia. - **Renal complications**: Chronic kidney disease is a common side effect. - **Cardiovascular disease**: A major cause of late mortality. - **Cancer risk**: Increased susceptibility to de novo malignancies, especially skin cancer. - **Tailored Immunosuppression**: Adjusting immunosuppressive regimens can help mitigate these risks. For example, minimizing calcineurin inhibitors may reduce renal toxicity. --- ### **3. Multidisciplinary Care** - **Collaboration**: Effective long-term management requires close collaboration between transplant centers and primary care physicians. This ensures a holistic approach to addressing the recipient's medical, psychological, and social needs. --- ### **4. Lifestyle and Wellness** - **Nutrition and Exercise**: Post-transplant care should prioritize: - A healthy diet to prevent weight gain and metabolic syndrome. - Regular aerobic and strength training to improve physical function, fitness, and quality of life. - **Weight Gain**: This is a common issue post-transplant and increases the risk of cardiovascular disease and metabolic dysfunction. Early intervention with lifestyle changes, and when necessary, pharmacologic or surgical weight-loss strategies, is critical. --- ### **5. Psychosocial Factors** - **Nonadherence Risks**: Medication and follow-up nonadherence are often linked to psychosocial stressors and mental health conditions. Addressing these issues through counseling and support programs is vital to ensure adherence. - **Alcohol Avoidance**: Alcohol use post-transplant is highly discouraged as it is associated with graft injury and poorer long-term outcomes. --- ### **6. Bone Health** - **Bone Disease**: Osteopenia and osteoporosis are prevalent among liver transplant recipients. Structured screening and preventive strategies are necessary to address these issues. - **Fracture Prevention**: Early detection and treatment of bone loss can reduce fragility fractures. Strategies include calcium and vitamin D supplementation, weight-bearing exercises, and pharmacologic therapies like bisphosphonates or denosumab. --- ### **7. Infection Management** - **Infection Risks**: Infections remain a leading cause of morbidity and mortality in transplant recipients due to immunosuppression. - **Prophylaxis**: Targeted antimicrobial prophylaxis is critical to reduce the risk of opportunistic infections, such as cytomegalovirus (CMV) and fungal infections. - **Vaccination**: Vaccination strategies must be carefully planned, avoiding live vaccines due to immunosuppression. Pre-transplant vaccination is ideal when possible. --- ### **8. Cancer Surveillance** - **Increased Cancer Risk**: Liver transplant recipients face a higher risk of de novo malignancies compared to the general population. - **Skin Cancer**: Routine dermatologic screening is essential due to the elevated risk of skin cancers, including squamous cell carcinoma and melanoma. Sun protection and regular dermatologic evaluations are recommended. --- ### **9. Cardiovascular Disease** - **Burden of Cardiovascular Disease**: Metabolic syndrome, obesity, and hypertension significantly contribute to cardiovascular disease, a major cause of late mortality. - **Management**: Strategies include lifestyle interventions, pharmacologic therapies for hypertension and dyslipidemia, and tailored immunosuppressive regimens to minimize cardiovascular risk. --- ### **10. Diabetes Management** - **Evolving Therapies**: Modern non-insulin therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, offer safer and more effective long-term glycemic control post-transplant. These therapies may also provide cardiovascular and renal protective benefits. --- ### **11. Obesity Management** - **Early Action**: Obesity is a common problem post-transplant and requires early intervention. When lifestyle measures fail, pharmacologic or surgical weight-loss strategies may be necessary to prevent associated complications. --- ### **12. Evidence Gaps** - **Need for Research**: Many of the recommendations in liver transplantation care are based on observational data. There is a pressing need for prospective research to fill these evidence gaps and refine guidelines further. --- ### **13. Key Preventive Measures** - **Routine Screening**: Regular screening for metabolic syndrome, cardiovascular disease, bone disease, and malignancies is crucial. - **Wellness Programs**: Structured programs focusing on nutrition, exercise, and mental health can significantly improve quality of life and long-term outcomes. --- ### Conclusion The AASLD–AST Practice Guideline on Adult Liver Transplantation emphasizes a holistic, multidisciplinary approach to post-transplant care. By addressing immunosuppression-related complications, promoting wellness, ensuring adherence, and managing comorbidities, healthcare providers can optimize long-term outcomes for liver transplant recipients. Continued research is essential to refine these practices and address current evidence gaps.

Donor Microbiota Signatures Predict Short-Term Liver Transplant Outcomes

Yes, donor microbiota signatures, specifically those derived from the intrahepatic microbiome, can predict short-term liver transplant outcomes. The study you referenced highlights several key findings that establish the predictive value of donor microbiota signatures in liver transplantation: ### 1. **Microbial DNA in Organ Preservation Solution (OPS) Reflects Donor Liver Microbiota** - The study used metataxonomic analysis of microbial DNA found in the organ preservation solution (OPS), which is collected during the storage of donor livers. - This microbial DNA was shown to closely reflect the intrahepatic and bile microbiota of the donor liver, rather than the gut microbiota, indicating that it is a reliable, non-invasive proxy for assessing the donor liver microbiome. ### 2. **Distinct Microbial Signatures Associated with Transplant Outcomes** - The study identified specific microbial signatures in the OPS that were linked to critical short-term post-transplant outcomes such as: - **Graft survival** - **Acute rejection** - **Hepatic artery thrombosis** - **Biliary complications** - Certain microbial genera were enriched in cases with adverse outcomes, while others were associated with more favorable clinical results. This suggests that the composition of the donor liver microbiome plays a role in influencing graft behavior and the recipient's immune response. ### 3. **Biological Relevance of Microbial Patterns** - The microbial data was integrated with host gene information through gene mining and functional enrichment analysis. This revealed that the microbial patterns associated with transplant outcomes were linked to immune and metabolic pathways critical to transplantation. - Transcriptomic analysis of donor liver biopsies supported this, showing that grafts with poor outcomes had: - Increased expression of inflammatory chemokines. - Reduced expression of genes related to metabolism and cellular repair. ### 4. **Predictive Power of Machine Learning Models** - Machine learning models trained on OPS microbial data were able to stratify transplant risk effectively. - These models demonstrated how microbial signatures could be used to predict early transplant outcomes, offering a practical tool for clinicians to assess graft quality and risk before transplantation. ### 5. **Advantages of OPS Microbial Profiling** - OPS microbial profiling is a rapid and non-invasive method for evaluating donor liver microbiota. - It does not pose any additional risk to donors or recipients and can be performed pre-implantation, allowing for real-time decision-making in the transplant process. ### Implications for Precision Transplant Medicine The findings position the donor liver microbiome as a previously underrecognized factor in liver transplantation. By identifying specific microbial signatures that correlate with outcomes, OPS microbial profiling emerges as a promising biomarker for: - **Risk stratification** of transplant recipients. - **Personalized interventions** aimed at modulating the donor microbiome to improve outcomes. - **Advancing precision transplant medicine**, where microbiome-informed strategies could be used to optimize graft success and recipient health. In conclusion, donor microbiota signatures derived from OPS microbial profiling are a powerful predictor of short-term liver transplant outcomes. They provide new insights into the role of the intrahepatic microbiome in transplantation and open the door to innovative approaches for improving post-transplant care.

AASLD–AST Guideline on Non-Graft Complications After Adult Liver Transplantation

The AASLD–AST (American Association for the Study of Liver Diseases–American Society of Transplantation) guideline focuses on the diagnosis, prevention, and management of non-graft-related complications that significantly impact the long-term health of adult liver transplant recipients. These complications arise beyond the initial 90 days post-transplantation and are increasingly recognized as key determinants of long-term morbidity and mortality, as opposed to graft failure itself. ### Key Highlights of the Guideline: #### 1. **Scope of the Guideline**: - The guideline specifically addresses health issues unrelated to graft failure but that contribute to poor outcomes in liver transplant recipients. - These complications are often subtle in onset, require proactive management, and may stem from chronic immunosuppression, recurrent liver disease, or other medical and surgical comorbidities. #### 2. **Non-Graft Complications Addressed**: The guideline identifies several critical non-graft-related complications: - **Metabolic Syndrome**: Includes obesity, diabetes, hypertension, and dyslipidemia, which are common in liver transplant recipients due to immunosuppressive therapy and lifestyle factors. - **Chronic Kidney Disease (CKD)**: A frequent and serious complication often linked to calcineurin inhibitor use. - **Cardiovascular Disease (CVD)**: A leading cause of mortality in this population, influenced by metabolic syndrome and pre-existing risk factors. - **Malignancies**: Liver transplant recipients are at an elevated risk of certain cancers, including post-transplant lymphoproliferative disorder (PTLD) and skin cancers, due to immunosuppression. - **Infections**: Opportunistic infections remain a concern, especially in the context of immunosuppressive medications. - **Bone Disease**: Osteoporosis and fractures are common due to corticosteroid use and pre-existing liver disease. - **Abdominal Wall Hernias**: A surgical complication that may arise after transplantation. #### 3. **Importance of Proactive Surveillance and Prevention**: - Many of these complications develop gradually and can be mitigated through early detection and preventive strategies. - Regular monitoring and risk factor management are critical to improving patient outcomes. #### 4. **Development of Recommendations**: - A multidisciplinary expert panel used the PICO (Population, Intervention, Comparator, Outcome) framework to define clinically relevant questions. - A systematic review of the literature was conducted, and recommendations were graded based on the Oxford Center for Evidence-Based Medicine. - The recommendations balance the available evidence, the risk–benefit ratio, and patient preferences. #### 5. **Care Coordination**: - The guideline emphasizes the need for long-term, coordinated care involving both transplant centers and primary care physicians. - A multidisciplinary approach is essential for addressing the diverse health challenges faced by liver transplant recipients. #### 6. **Evidence Gaps and Research Needs**: - The guideline acknowledges that many recommendations are based on retrospective studies, systematic reviews, or extrapolations from the general population due to a lack of high-quality prospective data specific to liver transplant recipients. - It highlights the urgent need for robust, prospective studies to optimize long-term outcomes in this population. ### Conclusion: The AASLD–AST guideline provides a comprehensive framework for managing non-graft-related complications in adult liver transplant recipients. It underscores the importance of proactive surveillance, prevention, and multidisciplinary care to address the complex health needs of these patients. While significant progress has been made in understanding and managing these complications, the guideline also calls for further research to fill existing evidence gaps and improve long-term outcomes.

AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation

The AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation provides a comprehensive, evidence-based framework for assessing patients who may benefit from liver transplantation. This updated guideline, developed by a multidisciplinary expert panel, reflects advancements in transplantation medicine, evolving patient populations, and ethical considerations since the previous 2005 guidance. It emphasizes equity, utility, and improving patient outcomes while ensuring consistent and transparent practices across transplant centers. ### Key Highlights of the Guideline: #### 1. **Indications for Referral to a Transplant Center** - **Decompensated Cirrhosis**: Patients with liver disease complications such as ascites, variceal bleeding, or hepatic encephalopathy should be referred. - **Acute-on-Chronic Liver Failure (ACLF)**: These patients should be considered for evaluation due to their high risk of mortality. - **Acute Liver Failure (ALF)**: This condition requires **urgent referral** to a transplant center due to its rapid progression and life-threatening nature. - **Hepatocellular Carcinoma (HCC)**: Patients with liver cancer, particularly those within transplant criteria (e.g., Milan criteria), are candidates for evaluation. - **Select Cholangiocarcinoma Cases**: Patients with early-stage cholangiocarcinoma may also be considered for transplantation. - **Portal Hypertensive Complications or Quality-of-Life Impairment**: Even in cases with low MELD (Model for End-Stage Liver Disease) scores, these factors should prompt consideration for referral. #### 2. **Principles of Candidate Evaluation** - The evaluation process focuses on: - **Prognosis Without Transplantation**: Assessing the likelihood of survival without a transplant. - **Post-Transplant Benefit**: Determining the potential for improved survival and quality of life after transplantation. - **Patient Preferences**: Incorporating the patient’s values, preferences, and goals of care into the decision-making process. - A **comprehensive multidisciplinary approach** is strongly recommended for evaluating candidates. #### 3. **Components of the Evaluation Process** The guideline recommends a thorough, multidisciplinary assessment to optimize outcomes: - **Cardiopulmonary Assessment**: Evaluating cardiovascular and pulmonary health to ensure suitability for surgery and recovery. - **Infection Screening**: Identifying and managing potential infections that could complicate transplantation. - **Cancer Surveillance**: Screening for malignancies to ensure they are within transplantable criteria. - **Nutrition and Frailty Assessment**: Evaluating nutritional status and physical frailty, as these factors can influence transplant outcomes. - **Bone Health**: Assessing for osteoporosis or other bone conditions that may impact recovery. - **Dental Health**: Ensuring oral health to minimize the risk of post-transplant infections. - **Psychosocial Assessment**: Addressing mental health, substance use disorders, social support, and adherence potential. #### 4. **Addressing Potential Contraindications** - The guideline emphasizes that certain conditions are **not absolute contraindications** to transplantation, provided the associated risks are managed effectively: - **Frailty**: While frailty is a risk factor, it is not an exclusion criterion if interventions can improve the patient’s condition. - **Mental Health Disorders**: These should be evaluated and treated but are not a reason to deny transplantation. - **Substance Use Disorders**: Patients with a history of substance use can be considered if they demonstrate sustained recovery and adherence potential. - **Extremes of BMI**: Obesity or underweight status should not automatically disqualify patients, though weight optimization may be necessary. #### 5. **Goals of the Guideline** - Standardize the evaluation process across transplant centers to ensure consistency. - Optimize patient outcomes by identifying the most appropriate candidates. - Reduce disparities in access to liver transplantation. - Support informed decision-making for both patients and healthcare providers. ### Summary The AASLD–AST guideline serves as a practical and ethical framework for evaluating adult liver transplant candidates. It stresses the importance of timely referral, comprehensive multidisciplinary evaluation, and addressing modifiable risk factors. By prioritizing equity and patient benefit, the guideline aims to improve outcomes and ensure fair access to this life-saving therapy.

Pediatric Immunosuppression

Pediatric immunosuppression is a critical aspect of care for children undergoing liver transplantation, aimed at preventing graft rejection while minimizing adverse effects. Recent studies, including the ChILiSFree study and other research, have provided valuable insights into optimizing immunosuppression strategies in pediatric liver transplant recipients. Below is a detailed overview of key findings and approaches: ### **1. Early Steroid Use Reduces Rejection** - **Key Evidence:** The ChILiSFree study demonstrated that early administration of steroids post-transplant significantly reduces the risk of T-cell–mediated rejection (TCMR) compared to tacrolimus monotherapy. - **Outcomes:** The biopsy-confirmed rejection rate was notably lower in the tacrolimus-plus-steroid group (15.9%) compared to the tacrolimus-only group (44.8%), showcasing the protective role of steroids. - **Mechanism:** Cytokine profiling revealed that steroids effectively suppress pro-inflammatory signals, correlating with reduced TCMR burden. ### **2. Strong Survival Outcomes** - **Patient and Graft Survival:** One-year patient survival was 98.0%, and graft survival was 92.7%, underscoring the safety and efficacy of early steroid-based immunosuppression. - **Clinical Significance:** These high survival rates highlight the importance of early intervention in reducing rejection and ensuring transplant success. ### **3. Feasibility of Steroid-Free Approaches** - **Alternative Protocols:** Tacrolimus–basiliximab therapy has been explored as a steroid-free option, with 44.7% of biliary atresia patients achieving steroid-free survival at six months. - **Graft Survival:** Despite steroid-free protocols, overall graft survival was high at 96.4%. - **Challenges:** Patients requiring steroids in the steroid-free cohort showed higher variability in tacrolimus levels and increased infection risks, emphasizing the need for careful monitoring. ### **4. Long-Term Success with Immunosuppression Minimization** - **Retrospective Findings:** Immunosuppression minimization strategies have demonstrated long-term success, with overall graft survival rates of 61% in selected pediatric recipients. - **Safety Profile:** When applied to low-risk patients, reduced immunosuppression did not lead to increased rejection, death, or graft loss, making it a viable long-term strategy. ### **5. Two-Phase Strategy for Pediatric Immunosuppression** - **Phase 1:** Early steroid use to prevent acute rejection during the critical post-transplant period. - **Phase 2:** Gradual and individualized immunosuppression minimization tailored to the patient’s risk profile. This approach balances efficacy and safety while reducing treatment-related morbidity. ### **6. Future Outlook** - **Personalized Care:** Emerging data supports the development of treatment protocols that prioritize personalized approaches, balancing immunosuppression efficacy with minimizing side effects. - **Research Implications:** These findings pave the way for innovative strategies that optimize long-term outcomes and quality of life for pediatric liver transplant recipients. ### **Conclusion** Pediatric immunosuppression strategies are evolving, with evidence supporting early steroid use to reduce rejection, followed by individualized immunosuppression minimization for sustained safety. While steroid-free approaches show promise, they require careful monitoring due to potential risks. The ultimate goal is to achieve a balance between preventing rejection and minimizing treatment-related morbidity, ensuring the best possible outcomes for pediatric liver transplant patients.

Benefit and harm of waiting time in liver transplantation for HCC

The waiting time in liver transplantation (LT) for hepatocellular carcinoma (HCC) has both benefits and potential harms, depending on its duration and the management strategies applied during this period. Below is a detailed breakdown of the benefits and harms of waiting time: --- ### **Benefits of Waiting Time in Liver Transplantation for HCC** 1. **Assessment of Tumor Biology ("Test-of-Time" Principle):** - A moderate waiting time of **6–8 months** allows for observation of tumor behavior, identifying aggressive tumors that may progress rapidly or metastasize. This helps in selecting patients with more favorable tumor biology who are likely to benefit from LT and achieve long-term survival. - Patients with stable disease during this period are more likely to experience lower recurrence rates post-transplant. 2. **Prevention of Premature Transplantation:** - Transplanting too early may result in the inclusion of patients with aggressive HCC that could recur post-transplant, reducing long-term survival rates. - Waiting ensures that only patients with tumors that meet transplant criteria (e.g., Milan or UCSF criteria) and show stability are prioritized for transplantation. 3. **Opportunity for Bridging Therapy:** - During the waiting time, locoregional therapies such as **transarterial chemoembolization (TACE)**, **radiofrequency ablation (RFA)**, or **transarterial radioembolization (TARE)** can be applied to control tumor growth and prevent progression. - Bridging therapy has been shown to improve post-LT outcomes by maintaining tumors within transplant criteria and achieving higher rates of complete tumor necrosis, which is associated with better survival and reduced recurrence. 4. **Equity and Regional Disparities:** - Policies like the **UNOS 6-month rule** standardize a minimum waiting period, reducing regional disparities in access to LT and improving fairness in organ allocation. - This approach also decreases the risk of recurrence by ensuring that only patients with stable disease are transplanted. 5. **Downstaging Success:** - For patients with tumors initially beyond transplant eligibility criteria, waiting allows time for **downstaging therapies** to reduce tumor burden. Successful downstaging followed by observation can lead to favorable outcomes and enable these patients to become eligible for LT. 6. **Integration of Biomarkers and Tumor Biology:** - Waiting time allows for the evaluation of biomarkers such as **alpha-fetoprotein (AFP)** and tumor molecular profiling (e.g., **TERT**, **TP53**, **CTNNB1 mutations**) to better predict tumor aggressiveness and refine patient selection. --- ### **Harm of Waiting Time in Liver Transplantation for HCC** 1. **Risk of Disease Progression:** - Prolonged waiting times increase the risk of tumor progression beyond transplant criteria, leading to patient dropout from the waitlist. This is particularly concerning for patients with aggressive tumor biology or high-risk features such as elevated AFP levels (>100–1000 ng/mL). 2. **Higher Pre-Transplant Mortality:** - Longer waiting times are associated with higher pre-transplant mortality due to disease progression or related complications. Patients in regions with longer wait times face worse pre-transplant outcomes. 3. **Missed Opportunity for Timely Transplantation:** - Excessive delays may result in patients losing their window of opportunity for transplantation due to advanced disease or other comorbidities. 4. **Psychological and Emotional Impact:** - Prolonged waiting times can lead to significant emotional stress, anxiety, and reduced quality of life for patients and their families. 5. **Impact of Socioeconomic Disparities:** - Access to transplantation and waiting times are influenced by factors such as race, geographic location, and insurance status. Patients in underserved regions or with limited resources may face disproportionately longer waiting times, exacerbating inequities in outcomes. --- ### **Optimal Balance:** - The **ideal waiting time** for liver transplantation in HCC is generally considered to be **6–8 months**, as it strikes a balance between allowing time to assess tumor biology and minimizing the risks of disease progression or dropout. - During this period, the use of **bridging therapies**, careful monitoring of tumor markers (e.g., AFP levels), and regular imaging to assess tumor stability are crucial in optimizing outcomes. --- ### **Future Directions:** - Advances in **tumor genetics**, **liquid biopsy**, and **emerging biomarkers** (e.g., circulating tumor DNA, DNA methylation markers like TSPYL5 and SPINT2) hold promise for refining the timing and selection criteria for LT. - Personalized approaches that integrate tumor biology, patient-specific factors, and waiting time optimization will further improve the balance between the benefits and harms of waiting for liver transplantation in HCC patients. --- In conclusion, while a moderate waiting time for liver transplantation provides the opportunity to evaluate tumor biology, apply bridging therapies, and ensure equitable organ allocation, excessively short or prolonged waiting times can lead to suboptimal outcomes. The key lies in achieving a balance that maximizes the long-term survival benefits while minimizing the risks of dropout and disease progression.

Targeted enteral feeding for malnutrition in liver transplant candidates

Targeted enteral feeding, specifically nasogastric feeding (NGF), has been studied as a potential strategy to address malnutrition in liver transplant candidates. Malnutrition is a critical concern in this patient population because it significantly impacts surgical recovery, post-transplant survival, and overall functional outcomes. Below is a detailed exploration of the topic based on Chapman et al.'s study and related insights: ### **Why Malnutrition Matters in Liver Transplant Candidates** 1. **Impact on Recovery and Survival:** Severe malnutrition is associated with increased risks of complications during and after liver transplantation. Nutritional deficits can impair immune function, wound healing, and muscle strength, which are crucial for recovery. 2. **Challenges in Nutritional Management:** Malnutrition in liver disease is multifaceted, often influenced by factors such as reduced appetite, metabolic alterations, and gastrointestinal symptoms. Correcting these deficits requires targeted interventions beyond standard dietary counseling. ### **Targeted Enteral Feeding (NGF) as a Strategy** 1. **Purpose of NGF:** Nasogastric feeding delivers nutrition directly to the stomach or small intestine, bypassing barriers like poor appetite or dietary non-compliance. It is a proactive approach to ensure patients meet their caloric and protein needs. 2. **Physiological Rationale:** Improved nutrition has been positively correlated with increased muscle mass, which is vital for physical function and recovery. NGF directly addresses the nutritional deficits seen in liver transplant candidates. ### **Key Findings from Chapman et al.'s Study** 1. **Control Group vs. NGF Group:** - Control participants received individualized dietary counseling, which exceeds standard care but achieved only 70% of caloric goals and 63% of protein targets. This highlights the difficulty of correcting malnutrition through counseling alone. - NGF participants had targeted feeding, which provided more consistent and measurable nutritional support. 2. **Underestimation of NGF Benefits:** Since both groups received nutritional interventions, the study may have underestimated the therapeutic potential of NGF. NGF likely offers greater benefits compared to standard care alone. 3. **Positive Correlation Between Nutrition and Muscle Mass:** The study demonstrated a link between improved nutrition and increased muscle mass, validating the physiological benefits of targeted feeding. However, causality was not definitively established. ### **Challenges and Limitations** 1. **Baseline Differences:** Variability in baseline nutritional status (e.g., body mass index and muscle mass) between the NGF and control groups may have confounded the results, reducing the study's statistical strength. 2. **Interpretation Limitations:** Without accounting for these baseline differences and other confounding factors, the observed benefits of NGF should be interpreted cautiously. 3. **Real-World Applicability:** The study design does not fully address how NGF protocols might be implemented in routine clinical practice for liver transplant candidates. ### **Need for Further Research** 1. **Larger, Randomized Trials:** The author emphasizes the need for larger studies with randomized designs to validate NGF’s long-term benefits and better understand its role in clinical transplant nutrition protocols. 2. **Optimizing Feeding Protocols:** Future research should focus on determining the most effective NGF protocols to maximize nutritional rehabilitation and functional outcomes. 3. **Addressing Confounding Factors:** Studies should aim to control for baseline differences and other variables to provide more definitive evidence of NGF’s causal benefits. ### **Overall Conclusion** Targeted enteral feeding, such as NGF, shows promise in addressing malnutrition and improving functional outcomes in liver transplant candidates. While Chapman et al.'s study provides valuable insights, it also underscores the need for more robust research to confirm NGF’s benefits, refine protocols, and ensure its practical application in clinical settings. For now, NGF appears to be a useful adjunct to standard nutritional care, particularly for patients with severe malnutrition who struggle to meet dietary goals through counseling alone.

Colorectal cancer liver metastasis (CRLM) and Liver Transplantation

Liver transplantation (LT) is emerging as a viable treatment option for colorectal cancer liver metastases (CRLM), offering promising outcomes for select patients. A large multicenter study analyzing 82 patients from 2006 to 2020 revealed favorable long-term survival rates, with 1-, 3-, and 5-year overall survival (OS) rates of 93.7%, 73.4%, and 54.9%, respectively. However, sex-based differences were significant, with female patients facing a fourfold higher mortality risk compared to males. Several factors influence post-LT survival. Adverse prognostic indicators include elevated carcinoembryonic antigen (CEA >80 µg/L), KRAS mutations, right-sided primary tumors, large tumor nodules (>5.5 cm), and pN2-positive lymph nodes. Right-sided colorectal cancer, often seen in women, is linked to worse outcomes due to aggressive tumor biology. Women also experienced more frequent liver recurrences, which negatively impacted survival compared to lung-only recurrences. Prior liver-directed therapies, such as resection or ablation, showed a protective effect, reducing post-transplant risks. Researchers propose that hormonal factors like oestrogens may influence immune tolerance and tumor progression in women, contributing to poorer liver recurrence outcomes. The study calls for sex-aware prognostic models and refined LT selection criteria, integrating molecular profiling and hormonal factors to improve equity and precision in CRLM treatment through liver transplantation.

Sedoanalgesia during TIPS placemen

Sedoanalgesia during transjugular intrahepatic portosystemic shunt (TIPS) placement refers to the combined use of sedation and analgesia to ensure patient comfort, pain relief, and reduced anxiety during this invasive procedure. TIPS is a complex interventional radiology procedure that involves creating a shunt between the portal and hepatic veins to manage complications of portal hypertension, such as variceal bleeding or refractory ascites. Given the invasive nature of the procedure, sedoanalgesia is critical for both ethical and physiological reasons. ### Importance of Sedoanalgesia During TIPS Placement: 1. **Patient Comfort and Welfare:** - TIPS placement involves catheter insertion, manipulation of blood vessels, and shunt creation, all of which can cause significant discomfort or pain. Sedoanalgesia ensures that patients remain comfortable and pain-free throughout the procedure. - Performing TIPS without adequate sedation and analgesia, as highlighted in the critique of the study by Lv et al., raises ethical concerns. The World Medical Association emphasizes the importance of pain management as a fundamental patient right. 2. **Reduction of Stress Responses:** - Without sedation, patients undergoing TIPS may experience significant stress, leading to physiological responses such as vagal activation (causing bradycardia) or adrenergic surges (causing tachycardia and hypertension). These responses can complicate the procedure and affect the accuracy of immediate portal pressure gradient (PPG) measurements. - Sedoanalgesia helps to stabilize hemodynamics by minimizing stress-induced fluctuations, ensuring more reliable and consistent PPG readings post-TIPS. 3. **Ethical and Procedural Standards:** - International guidelines recommend the use of appropriate sedation and analgesia for invasive procedures like TIPS. These guidelines aim to uphold ethical standards in medical practice by prioritizing patient safety, dignity, and comfort. 4. **Facilitation of Procedural Success:** - An awake and anxious patient may move or react to discomfort during TIPS, increasing the risk of complications or procedural failure. Sedoanalgesia helps achieve patient cooperation, facilitating a smoother and safer procedure. ### Types of Sedoanalgesia Used in TIPS: Sedoanalgesia typically involves a combination of sedative and analgesic medications. The choice of drugs depends on the patient's medical condition, the complexity of the procedure, and the clinical setting. Commonly used medications include: - **Sedatives:** - Midazolam: A benzodiazepine that provides sedation and anxiolysis. - Propofol: A short-acting sedative that allows rapid recovery after the procedure. - **Analgesics:** - Fentanyl: A potent opioid analgesic for pain relief. - Morphine or other opioids: Used for managing procedural pain. The level of sedation can range from moderate sedation (conscious sedation, where the patient is awake but relaxed) to deep sedation (where the patient is asleep but can still respond to stimuli). General anesthesia is rarely used unless clinically indicated. ### Recommendations for Sedoanalgesia in TIPS: The critique of Lv et al.'s study emphasizes the need for standardized global guidelines for sedation and analgesia during TIPS placement. These guidelines should: 1. Ensure routine use of sedoanalgesia to uphold ethical standards and prioritize patient welfare. 2. Address the physiological implications of sedation to ensure accurate hemodynamic assessments, such as PPG measurements. 3. Provide clear protocols for the choice and administration of sedatives and analgesics, tailored to individual patient needs. 4. Encourage training for healthcare providers in sedation techniques to ensure safe and effective implementation. In summary, sedoanalgesia during TIPS placement is essential for ethical compliance, patient comfort, and procedural success. It minimizes stress responses, ensures accurate hemodynamic measurements, and aligns with international standards for invasive interventions. Developing and adhering to standardized guidelines will help improve patient outcomes and advance clinical practice in this area.

Novel biomarkers, liver regeneration following plasma exchange in ALF

Liver regeneration is a critical biological process where the liver repairs and restores its tissue following injury or damage. In the context of acute liver failure (ALF), liver regeneration is especially significant, as it determines whether the patient can recover without requiring a liver transplant. Plasma exchange (PEX) is a therapeutic intervention used in ALF to stabilize patients by removing toxic substances, modulating inflammation, and potentially creating a favorable environment for liver regeneration. However, predicting which patients will successfully regenerate their liver following PEX remains challenging, necessitating the identification of novel biomarkers. ### **Liver Regeneration in Acute Liver Failure (ALF):** - **Mechanism of Liver Regeneration:** The liver has a unique ability to regenerate after injury. Hepatocytes (liver cells) re-enter the cell cycle and proliferate to replace damaged tissue. This process is regulated by various growth factors, cytokines, and signaling pathways, including the hepatocyte growth factor (HGF), transforming growth factor-beta (TGF-β), and interleukin-6 (IL-6). - **Challenges in ALF:** In ALF, the regenerative capacity of the liver can be impaired due to overwhelming injury, systemic inflammation, and metabolic disturbances. Regeneration is highly variable among patients, making it difficult to predict outcomes. ### **Biomarkers for Liver Regeneration:** Biomarkers are measurable indicators of biological processes, such as liver regeneration. Identifying reliable biomarkers can help predict which ALF patients are most likely to benefit from PEX therapy. Biomarkers for liver regeneration can be broadly categorized into traditional and novel biomarkers. #### **Existing Biomarkers:** 1. **Alpha-Fetoprotein (AFP):** - AFP is a protein produced during liver regeneration and has been associated with transplant-free survival in ALF patients. - Limitations: AFP levels can be inconsistent and lack strong predictive power, limiting its widespread adoption. 2. **Inflammatory Markers:** - Reduction in systemic inflammation following PEX, such as decreased levels of IL-6, TNF-alpha, and C-reactive protein (CRP), may indirectly indicate improved conditions for liver regeneration. - However, these markers primarily reflect inflammation rather than regeneration itself. 3. **Traditional Scoring Models:** - Prognostic models like the King’s College criteria focus on disease severity but fail to adequately predict liver regenerative potential or recovery post-PEX. #### **Novel Biomarkers for Liver Regeneration Following PEX:** 1. **MicroRNAs (miRNAs):** - **What are miRNAs?** MicroRNAs are small, non-coding RNA molecules that regulate gene expression and play a critical role in various biological processes, including liver regeneration. - **Evidence in Liver Regeneration:** - Specific miRNA signatures have been identified in patients undergoing auxiliary liver transplantation, where successful native liver regeneration was observed. - Similar miRNA profiles have been found in ALF patients achieving transplant-free survival and in cirrhosis patients recovering after hepatitis C treatment. - **Advantages of miRNAs:** - miRNAs are highly specific and can directly reflect regenerative activity in the liver. - A novel miRNA-based prognostic model for acetaminophen-induced ALF has shown superior accuracy compared to traditional scoring systems. - **Challenges:** - Clinical implementation of miRNA biomarkers faces obstacles such as technical complexity, standardization issues, and the high cost of molecular testing. 2. **Regeneration-Associated Growth Factors:** - Growth factors such as hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) may serve as potential biomarkers for liver regenerative capacity. Their levels could indicate the liver’s ability to repair itself after PEX. 3. **Proteomic and Metabolomic Biomarkers:** - Advanced techniques like proteomics and metabolomics are being explored to identify novel biomarkers linked to liver regeneration. These approaches analyze the protein and metabolic profiles of patients to uncover regeneration-specific patterns. 4. **Inflammation-Modulation Biomarkers:** - Reduction in inflammatory markers post-PEX, like IL-6 and TNF-alpha, may create a favorable environment for hepatocyte proliferation. While not direct indicators of regeneration, they could complement regenerative biomarkers. ### **Clinical Significance of Novel Biomarkers:** - **Improved Patient Selection:** Regenerative biomarkers, especially miRNA-based models, could help identify ALF patients most likely to benefit from PEX therapy, preventing unnecessary interventions in non-responders. - **Optimized Outcomes:** By focusing on liver regenerative potential rather than disease severity, clinicians can tailor therapies to maximize recovery and survival rates. - **Reduced Mortality:** Accurate prognostic tools could lead to timely interventions, reducing mortality in ALF patients. ### **Research and Translational Challenges:** - **Variability in Patient Responses:** The regenerative capacity of the liver varies widely among individuals, making biomarker validation difficult. - **Standardization Issues:** Developing standardized protocols for biomarker measurement and interpretation is essential for clinical implementation. - **Cost and Accessibility:** Molecular testing for novel biomarkers like miRNAs can be expensive, limiting widespread use. ### **Conclusion:** Novel biomarkers, particularly miRNAs, hold great promise for predicting liver regeneration following plasma exchange in ALF patients. These biomarkers can provide precise insights into the liver’s intrinsic regenerative capacity, enabling better patient selection and improved therapeutic outcomes. Continued translational research is essential to validate these biomarkers and integrate them into routine clinical practice, ultimately refining the management of ALF and optimizing the use of plasma exchange therapy.

Therapeutic plasma exchange in acute liver failure

Therapeutic plasma exchange (TPE) is a medical procedure used to remove and replace a patient's plasma, which can contain harmful substances or toxins contributing to disease pathology. In the context of acute liver failure (ALF), TPE has emerged as a potential therapeutic intervention aimed at improving native liver survival, stabilizing patients, and potentially serving as a bridge to liver transplantation (LT) in certain cases. ### **How TPE Works in Acute Liver Failure** Acute liver failure is a life-threatening condition characterized by the sudden loss of liver function, often accompanied by coagulopathy, encephalopathy, and multi-organ dysfunction. In ALF, the liver is unable to effectively clear toxins, regulate metabolic processes, or synthesize essential proteins. TPE works by mechanically removing the patient's plasma, which contains toxins, inflammatory mediators, and other harmful substances, and replacing it with donor plasma or albumin solutions. This process aims to: 1. **Clear Circulating Toxins:** TPE removes substances such as bilirubin, ammonia, and inflammatory cytokines that accumulate due to liver dysfunction. These toxins can exacerbate systemic inflammation and multi-organ failure. 2. **Restore Homeostasis:** By replacing the plasma with fresh donor plasma, TPE provides missing clotting factors, albumin, and other essential proteins, which may temporarily stabilize the patient's condition. 3. **Reduce Inflammation:** The removal of pro-inflammatory cytokines and mediators can help mitigate systemic inflammatory response syndrome (SIRS), which is common in ALF and contributes to multi-organ failure. 4. **Support Native Liver Recovery:** In cases where the liver has the potential to regenerate, TPE may reduce the toxic burden and create a more favorable environment for recovery. ### **Key Factors Influencing TPE Efficacy in ALF** The success of TPE in managing ALF depends heavily on factors such as timing, patient selection, plasma volume exchanged, and the underlying etiology of ALF. #### 1. **Timing of Intervention** - **Early Initiation:** TPE is most effective when initiated early, before the onset of severe multi-organ failure and hemodynamic instability. Early intervention can prevent the progression of systemic inflammation and organ dysfunction, improving survival outcomes. - **Late Initiation:** TPE initiated in patients with advanced multi-organ failure or hemodynamic instability has limited efficacy, as the disease may have progressed beyond the point where toxin clearance can significantly alter outcomes. #### 2. **Patient Selection** - **Appropriate Candidates:** TPE is most beneficial in patients with toxin- or infection-related ALF, such as acetaminophen overdose, hepatitis A, yellow phosphorus poisoning, or Wilson’s disease. These etiologies are more likely to respond to toxin clearance and inflammatory modulation. - **Contraindications:** Patients with contraindications to liver transplantation (e.g., severe hemodynamic instability) or those in advanced stages of multi-organ failure may derive limited benefit from TPE. #### 3. **Plasma Volume Exchanged** - **Optimal Exchange Volumes:** Studies suggest that high-volume or standard-volume TPE (8–12 liters or 1.5–2 plasma volumes) is necessary to achieve significant toxin clearance and improve clinical outcomes. Insufficient plasma exchange volumes (e.g., 4 liters, as seen in some studies) may fail to achieve therapeutic thresholds. - **Bilirubin Reduction:** A decline in bilirubin levels during TPE is often used as a marker of efficacy, as bilirubin reduction typically parallels clinical improvement. #### 4. **Underlying Etiology** - **Etiology-Specific Benefits:** TPE has shown particular efficacy in toxin-related ALF cases (e.g., acetaminophen overdose, Wilson’s disease) and certain infections (e.g., hepatitis A). In contrast, its role in autoimmune or cryptogenic ALF is less clear. - **Pediatric ALF:** In pediatric patients, particularly those with hepatitis A-related ALF, TPE has demonstrated significantly improved native liver survival rates. ### **Current Evidence and Limitations** #### **RCTs and Clinical Studies** - **Randomized Controlled Trials (RCTs):** Previous RCTs, such as Larsen et al. and Maiwall et al., have shown improved survival outcomes when TPE is initiated early in ALF patients without severe multi-organ failure. These studies highlight the importance of intervention timing and patient selection. - **Multicenter Study Critique:** A study by Burke et al. demonstrated limited efficacy of TPE, likely due to delayed initiation in patients with advanced disease and insufficient plasma exchange volumes. This underscores the need for optimal protocols. #### **Challenges** 1. **Late Referral:** Patients often arrive at specialized liver transplant centers after significant disease progression, delaying TPE initiation. 2. **Suboptimal Plasma Volumes:** Insufficient plasma exchange volumes may fail to clear enough toxins to achieve therapeutic benefit. 3. **Evolving Practices:** Data from earlier studies may not reflect improvements in TPE protocols and patient selection criteria in recent years. ### **Role of TPE as a Bridge to Liver Transplantation** While TPE does not appear to improve post-transplant survival directly, it may stabilize patients preoperatively by: - Reducing the need for vasopressors (inotropes). - Shortening ICU stays. - Improving hemodynamic status, making patients more suitable candidates for transplantation. ### **Illustrative Timing Model** The timing of TPE intervention can be visualized in three disease slopes: 1. **Early Deterioration (Slope A):** TPE is beneficial in this phase, as it can prevent progression to multi-organ failure. 2. **Recovery Phase (Slope B):** TPE may be harmful during this phase, as it could remove growth factors necessary for liver regeneration. 3. **Late Failure (Slope C):** TPE is ineffective in this phase, as the disease has progressed too far for toxin clearance to influence outcomes. ### **Conclusion** Therapeutic plasma exchange represents a promising intervention in the management of acute liver failure, particularly when initiated early and in carefully selected patients. To maximize its efficacy: - TPE should be started before the onset of multi-organ failure and hemodynamic instability. - High-volume plasma exchange protocols should be used to achieve optimal toxin clearance. - Patient selection should focus on cases with toxin- or infection-related etiologies, where native liver recovery is feasible. Further research incorporating updated protocols and real-world data is needed to refine TPE’s role in ALF management and improve survival outcomes.

LTSI consensus guidelines for the management of acute liver injury caused by yellow phosphorus

The Liver Transplant Society of India (LTSI) consensus guidelines for the management of acute liver injury (ALI) caused by yellow phosphorus (YP) poisoning emphasize the critical need for early recognition, hospitalization, supportive care, and timely referral for liver transplantation (LT), given the high mortality associated with this condition. Below are the key recommendations and management principles derived from the guidelines: --- ### **1. Clinical Importance and Patient Demographics** - **High Mortality:** Yellow phosphorus poisoning is a significant cause of acute liver failure (ALF) in India, with mortality rates ranging from 20%–30%. - **Target Population:** Most cases involve young adults (20s–40s) due to suicidal ingestion, though pediatric accidental exposures and poisoning via fireworks are also reported. --- ### **2. Toxic Mechanisms** - Yellow phosphorus causes hepatotoxicity through: - Mitochondrial damage. - Inhibition of oxidative phosphorylation and ATP depletion. - Disruption of protein synthesis. - Other affected organs include the bone marrow, heart, pancreas, and muscles. --- ### **3. Clinical Course** YP poisoning progresses through three overlapping phases: 1. **Early Phase:** Gastrointestinal symptoms such as vomiting and abdominal pain. 2. **Quiescent Phase:** Silent biochemical injury without overt symptoms. 3. **Toxic Hepatitis and Multiorgan Failure:** Develops typically after day 4, with rapid deterioration. --- ### **4. Early Hospitalization** - **Mandatory Admission:** All patients with suspected or confirmed YP ingestion should be hospitalized, even if asymptomatic initially, as silent liver injury can progress to ALF. --- ### **5. Initial Management** - **Supportive Care:** - Correct fluid and electrolyte imbalances. - Administer vitamin K to counteract anticoagulant effects (common in rodenticides). - Consider early initiation of **N-acetylcysteine (NAC)**. - **Gastric Lavage:** Not recommended due to risks of aspiration and chemical burns. - **Activated Charcoal:** May be used within hours of ingestion to reduce toxin absorption. --- ### **6. Role of N-Acetylcysteine (NAC)** - NAC improves outcomes if started early (ideally within 6 hours of ingestion). - Delayed initiation reduces its efficacy but is still beneficial in mitigating liver injury. --- ### **7. Discharge Criteria** - Patients can be discharged if: - They do not develop acute liver injury within 5 days of ingestion. - They recover clinically and biochemically. - Close outpatient follow-up is essential. --- ### **8. Intensive Care Unit (ICU) Admission** - ICU monitoring is required for any evidence of organ injury. - Monitor for: - Encephalopathy. - Worsening INR. - Renal dysfunction. --- ### **9. Referral to Liver Transplantation Units** - **Early Referral:** Contact a liver transplant center as soon as ALF or significant liver injury is suspected. - **Timely Transfer:** Delay in transfer reduces survival chances. - The decision depends on: - Disease severity. - Local resources. - Travel logistics. --- ### **10. Extracorporeal Therapies** - **Therapeutic Plasma Exchange (TPE):** - Reduces toxin load and may improve transplant-free survival. - Practices regarding timing, dosing, and stopping criteria vary among centers. - Multicenter trials are needed to standardize its use. - **Renal Replacement Therapy (RRT):** - Essential for managing acute kidney injury (AKI) caused by direct toxicity or rhabdomyolysis. - Helps control ammonia levels and provides renal support. --- ### **11. Liver Transplantation (LT)** - **Indications for LT:** - Classic King’s College Criteria (KCC) are less predictive in YP poisoning. - Predictors include: - Encephalopathy ≥ grade 2. - MELD score ≥ 36. - INR > 6. - INR > 2.5 after 2 TPE cycles. - Encephalopathy ≥ grade 2 is considered the single most important predictor of irreversible liver injury and is the primary criterion for urgent LT listing. - **Contraindications for LT:** - Irreversible neurological damage is the only absolute contraindication. - Other organ failures may recover post-LT, especially in young patients. - **Type of LT:** - Both living donor and deceased donor liver transplants are viable. - Auxiliary transplants are associated with poorer outcomes, so standard orthotopic LT is preferred. --- ### **12. Medicolegal and Counseling Aspects** - All YP poisonings are medicolegal cases. - Physicians must: - Ensure proper documentation and reporting to legal authorities. - Provide psychological counseling for patients and families. - Offer post-discharge mental health support to address suicidal tendencies or accidental exposures. --- ### **13. Summary of Key Management Steps** 1. **Early Recognition and Admission:** - Hospitalize all patients with YP ingestion, even if asymptomatic. 2. **Supportive Care:** - Correct fluids, electrolytes, and coagulation parameters. - Initiate NAC early. 3. **Monitor Progression:** - Watch for signs of liver injury, encephalopathy, and multi-organ failure. 4. **Referral to LT Centers:** - Initiate early contact with transplant centers for timely intervention. 5. **Extracorporeal Therapies:** - Use TPE and RRT as needed for toxin removal and renal support. 6. **Liver Transplantation:** - Assess for LT based on encephalopathy and other predictors. 7. **Post-Discharge Care:** - Ensure close follow-up and mental health support. --- The LTSI guidelines highlight the importance of a multidisciplinary approach involving hepatologists, intensivists, transplant surgeons, and mental health professionals to optimize outcomes in patients with YP poisoning.